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ABSTRACT 
An Evaluation of GABAB Receptors on Modulating Neuroinflammation in a Non-
Transgenic Animal Model of Alzheimer’s Disease 
 
by 
Monica Michelle Bolton 
Dr. Jefferson Kinney, Examination Committee Chair  
Associate Professor of Psychology 
University of Nevada, Las Vegas 
 
 
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive 
memory loss and distinct neuropathological hallmarks, including amyloid beta plaques (Ab) and 
neurofibrillary tau tangles (NFT). Although the etiology remains to be discovered, several risk 
factors exist that significantly contribute to developing AD. Diabetes is one of the major risk 
factors associated with AD and is characterized by disrupted insulin signaling that may contribute 
to or exacerbate AD pathologies. Furthermore, both disorders result in increased 
neuroinflammation. Considerable evidence has demonstrated that a chronic inflammatory 
response, in particular chronic microglia activation, promotes Ab production as well as the 
hyperphosphorylation of tau through the sustained release and increased levels of several pro-
inflammatory cytokines. These data make understanding the mechanisms driving the 
inflammatory response and treatment of the inflammation an important target in AD research. In 
addition to aberrant microglia functioning, the loss of a number of aspects of GABAergic 
signaling, including GABAB
 
receptors, have been reported in clinical AD populations and animal 
models of AD. As microglia express functional GABAB receptors and activation on microglia 
appear to reduce their activity, GABA signaling may result in a decrease in pro-inflammatory 
cytokine production. Therefore, the purpose of this study is to investigate the role of GABAB in 
 iv 
neuroinflammation encompassing to AD pathogenesis using a non-transgenic animal model 
related to diabetes. Using a low-dose schedule of streptozotocin (STZ) administration to induce a 
sustained hyperglycemic state, we treated with animals with a GABAB receptor agonist (baclofen) 
to reduce activated microglia and pro-inflammatory effects. We found that STZ administration led 
to significantly increased blood glucose levels, memory impairments in the novel object 
recognition task, hyperphosphorylated tau, increased activated microglia, and pro-inflammatory 
cytokines. Treatment with baclofen ameliorated the above changes induced by STZ. Therefore, 
GABAB receptors play a role in modulating microglia function and neuroinflammation.    
 v 
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CHAPTER 1 
INTRODUCTION 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that affects up to 
11-16 million people worldwide (Alzheimer's Association, 2016). AD diagnoses is increasing at 
an alarming rate due to the rapid aging of the global population. Someone in the United States will 
develop AD every 66 seconds. By 2050, this rate of development is expected to raise to every 33 
seconds (Alzheimer's Association, 2016). The cost of AD on family members, caregivers, and/or 
nursing home fees result in a financial burden of approximately $221 billion (Alzheimer's 
Association, 2016). Clinical symptoms of AD include the progressive memory loss and decline in 
cognitive functions, which may lead to behavioral alterations including anxiety, psychosis, and 
confusion (Cummings et al., 2008). The pathological hallmarks of AD are amyloid b (Ab) plaques 
and neurofibrillary tau tangles (NFT) which eventually lead to neuronal loss (Glenner and Wong, 
1984; Grundke-Iqbal et al., 1986).  
According to the amyloid hypothesis of AD, the progression of the disorder is speculated 
to begin with the gradual accumulation and aggregation of Ab peptides leading to a molecular and 
cellular cascade that eventually results in synaptic alterations, microglial activation, and  insoluble 
tau helical filaments (Haass and Selkoe, 2007). Genetic factors are associated with the 
development of AD pathologies; however, 95-99% of AD cases (referred to as sporadic AD) are 
not accounted for by genetics alone (Alzheimer's Association, 2016). Risk factors including 
advanced age and Type 2 diabetes mellitus have been associated with the development of sporadic 
AD (Haan, 2006). Approximately 80% of patients with AD have a form of insulin dysregulation 
and patients with diabetes are twice as likely to develop AD (Ott et al., 1996; Janson et al., 2004).  
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Neuroinflammation is associated with both AD and diabetes (Srodulski et al., 2014). While 
inflammation in the brain can play a beneficial role in reducing AD pathologies during the early 
stages of the disorder, chronic neuroinflammation has been shown to exacerbate Ab aggregation 
and plaque formation as well as increased tau hyperphosphorylation (Glass et al., 2010; Rubio-
Perez and Morillas-Ruiz, 2012). Microglia, the main driver of the immune response in the brain, 
are found in abundance clustered near Ab plaques in AD brains (Rezai-Zadeh et al., 2011; Jay et 
al., 2015). In response to injury or stressors, these immune cells release pro-inflammatory 
cytokines. When left unchecked, continued release of pro-inflammatory cytokines can contribute 
to pathology and disease progression. However, the mechanisms that contribute to the sustained, 
chronic inflammation in AD are not entirely understood. 
One possible method of regulating or suppressing microglial activation may be through 
endogenous inhibitory neurotransmitter activity. Gamma-aminobutryic acid (GABA) is the main 
inhibitory neurotransmitter in the brain and recent evidence suggests that GABAergic signaling 
undergoes profound pathological changes in AD resulting in decreased neurotransmission and 
receptor expression (Iwakiri et al., 2005; Yanfang Li et al., 2016). The loss of function due to 
reduction of the neuronal expression of GABAB receptor could have detrimental effects, as these 
receptor subtypes play a role in oscillatory activity associated with memory and cognitive 
functioning (Brown et al., 2007). Interestingly, microglia also express functional GABAB 
receptors (Kuhn et al., 2004). In a cell culture study, the administration of a GABAB receptor 
agonist, baclofen, attenuated the release of pro-inflammatory cytokines from microglia after an 
immune challenge (Kuhn et al., 2004). Therefore, it is interesting to speculate the 
neuroinflammatory effects of GABAB receptor activation on AD pathologies.  
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The purpose of this study is to evaluate the role of GABAB receptors as it relates to 
neuroinflammation in an animal model utilizing risk factor diabetes mellitus to recapitulate aspects 
of AD pathology. Streptozotocin (STZ) is commonly used in research to disrupt insulin production 
and altered insulin signaling that results in similar pathologies with sporadic AD, including 
neuroinflammation. In this experiment, we found that a low-dose (40 mg/kg), staggered 
administration schedule resulted in sustained, elevated blood glucose levels (indicative of insulin 
dysregulation). After STZ administration, a subset of animals received the GABAB receptor 
agonist, baclofen, twice a day for two weeks with the goal of reducing neuroinflammation for a 
sustained period of time. Following which, learning and memory was assessed in two tasks 
commonly used in AD rodent models (novel object recognition and cued and contextual fear 
conditioning). The results demonstrated that baclofen ameliorated the STZ-induced memory 
impairments in the novel object recognition task while no significant learning impairments were 
observed in cued and contextual fear conditioning. Baclofen administration reduced 
neuroinflammatory markers and rescued protein changes associated with AD that were altered 
with the STZ administration. These data suggest that GABAB receptors can modulate microglia 
function and neuroinflammation that can rescue memory impairments and AD pathological 
markers.  
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CHAPTER 2 
REVIEW OF RELATED MATERIAL  
Alzheimer’s Disease Neuropathological Hypotheses 
Alzheimer’s disease (AD) is characterized clinically by a progressive decline in memory 
and cognitive functions. Initial clinical diagnosis is determined by a physician using neurological 
and clinical tests as well as blood and brain imaging. These symptoms vary among individuals; 
however, the most common initial symptom is the progressive inability to remember new 
information due to the hippocampal region being the first area affected in this disorder (Padurariu 
et al., 2012). The core clinical symptoms of AD include memory loss that disrupts daily life, 
challenges in problem solving or planning, difficulty to completing familiar tasks, trouble 
understanding visual images and spatial relationships, increase anxiety, agitation, sleep 
disturbances, etc. (Alzheimer's Association, 2016). Confirmation of diagnosis is made postmortem 
by the examination of senile amyloid-b (Ab) plaques and neurofibrillary tau tangles (NSTs) in the 
brain, particularly in the hippocampus. These neuropathological hallmarks of the disorder lead to 
neuronal cell loss that occur before any noticeable clinical symptoms (Mattson, 2008). The initial 
cause of the pathological symptoms is unknown; however, researchers speculate that the 
accumulation of Ab followed by the deposition of  NFTs triggers the onset of synaptic and 
neuronal dysfunction and subsequent neuronal loss (Hardy and Higgins, 1992).  
Ab plaques are extracellular structures composed of amyloid b peptides 40-42 amino acids 
in length. Ab peptides are generated by proteolytic cleavage of b-amyloid precursor protein (APP) 
and are normal products of APP metabolism that occurs throughout life (Hardy and Selkoe, 2002). 
APP is a single-transmembrane, receptor-like protein found ubiquitously in neuronal and non-
neuronal cells and has also been discovered circulating in extracellular fluids like cerebrospinal 
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fluid (CSF) and plasma (Haass et al., 1992; Seubert et al., 1992; Shoji et al., 1992; Busciglio et 
al., 1993). Processing of APP is mediated by two membrane-bound proteases, a-secretase or b-
secretase (also known as b-site APP-cleaving enzyme (BACE); (Haass, 2004). Following BACE 
cleavage, a special type of protease complex that is mediated by g-secretase along with obligatory 
presenilin-1 (PS1) or PS2, nicastrin, anterior pharynx-defective 1 (APH1), and presenilin enhancer 
2 (PEN2) makes an intramembrane scission to APP (Wolfe et al., 1999; Steiner et al., 2000; 
Kimberly et al., 2003; Takasugi et al., 2003; Edbauer et al., 2003; Haass, 2004). There are variable 
sites at which this complex cuts but it is the final cut at the g-site that releases Ab into biological 
fluids. Variability with the g-cut can occur and lead to Ab amino acids 38, 40, or 42, with the Ab42 
peptide having a readiness to self-aggregate leading to the pathogenicity of Ab (Borchelt et al., 
1996). 
Several lines of evidence suggest aberrant APP processing in AD. One of the first 
indications of the role of APP in AD comes from individuals with Down syndrome. Young adults 
with Down syndrome display the clinical and histopathological signs of AD, including plaques 
containing Ab and NFT (KE Wisniewski et al., 1985). These individuals have a third copy of 
chromosome 21, the location where the APP gene is located, prompting researchers to investigate 
mutations of APP in AD (Holtzman et al., 1996). It was subsequently found that all known 
mutations linked to familial AD, or early on-set AD, affect APP processing or the propensity of 
Ab aggregation (Heppner et al., 2015). For example, certain mutations in the genes that encode 
the presenilin proteins favor the cleavage of APP by g-secretases (Citron et al., 1992; X-D Cai et 
al., 1993; Suzuki et al., 1994) and separate mutations in APP result in a high self-aggregation of 
Ab into amyloid fibrils (T Wisniewski et al., 1991). These mutations result in toxic amyloidgenic 
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Ab plaques consisting mostly of Ab42, as observed by transgenic mice and cell lines harboring 
human APP mutations (LaFerla and KN Green, 2012; Heppner et al., 2015).  
Ab can coexist as monomers, oligomers, protofibrils, fibrils and Ab plaques with varying 
levels of pathogenic impact. Soluble oligomers are Ab assemblies that can bind to other 
macromolecules or cell membranes and become insoluble. Oligomers can aggregate to form 
protofibrils then fibrils which are the basis of plaques. Differences exist in aggregation between 
the soluble oligomers Ab40 and Ab42. Due to the extended length in amino acid number of Ab42 
and conformational freedom of its N termini, Ab42 forms less compact fibrils compared to the 
more compact form resulting from Ab40 (Roychaudhuri et al., 2009). Fibrils are aggregates of Ab 
with a b structure that make up insoluble plaques found in AD (Cavallucci et al., 2012). 
Surprisingly, plaque number does not correlate significantly with neuronal death and cognitive 
impairment (McLean et al., 1999), whereas soluble Ab oligomers appear to be more detrimental 
(Haass and Selkoe, 2007).   
Previous, somewhat crude methods of analyzing Ab plaque deposition in postmortem brain 
tissue of AD patients used two-dimensional plaque counts that can miss small, heterogeneous Ab-
assembly forms listed above. More precise methods using specific Ab enzyme-linked-immuno-
sorbent assays (ELISAs), along with western blotting and mass spectrometry, allows for a 
multifactorial analysis of Ab quality and quantity that can be further correlated with cognitive 
measures. Soluble Ab correlates better with cognitive deficits compared to plaque counts (Lue et 
al., 1999; McLean et al., 1999; Jun Wang et al., 1999; Näslund et al., 2000; Haass and Selkoe, 
2007). It is difficult to deduce whether large accumulation of insoluble Ab contribute solely to 
neuronal injury, as they are surrounded by a number of smaller, diffusible oligomers (Haass and 
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Selkoe, 2007). Soluble, low-number oligomers can inhibit hippocampal long-term potentiation 
(LTP) as observed in cell cultures (Townsend et al., 2006) and interfere with memory of learned 
behavior in wake, behaving rats (Cleary et al., 2005). Therefore, soluble, low-number oligomers 
are considered more toxic and detrimental than plaques in AD. 
Several risk factors associated with sporadic AD and Ab aggregation have recently been 
discovered. Evidence from genome-wide association studies (GWAS) confirm expression of the 
e4 allele of the APOE gene with increased risk of sporadic AD (Harold et al., 2009; Lambert et 
al., 2009). The APOE gene is found in three alleles: e2 (8.4% frequency), e3 (77.9% frequency), 
and e4 (13.7% frequency; (Farrer et al., 1997). Increased frequency of AD and lower age of onset 
is associated with APOE e4, with approximately 40% of AD patient as carriers of two e4 alleles 
(Corder et al., 1993; Rebeck et al., 1993; Farrer et al., 1997). Apolipoprotien E protein (ApoE) is 
found in liver and macrophages where it regulates cholesterol metabolism and lipid homeostasis 
(Mahley and Rall, 2000). ApoE4 carriers have an increased risk of developing atherosclerosis, 
coronary heart disease, and stroke (Mahley and Rall, 2000; Lahoz et al., 2001). In the central 
nervous system (CNS), ApoE (produced mainly by astrocytes) transports cholesterol to neurons 
through ApoE receptors (Bu, 2009). Several studies in humans and rodent models provide 
evidence that Ab are modulated by the ApoE isoform (with e4 having increased plaque load and 
e2 being protective), which suggests its role in metabolism and aggregation of Ab (Reiman et al., 
2009; Bales et al., 2009; Castellano et al., 2011). For instance, in APP transgenic mice, ApoE4 is 
less efficient at Ab clearance (Castellano et al., 2011). Furthermore, ApoE deficient mice are able 
to clear Ab more effectively compared to control mice (DeMattos et al., 2004). Although studies 
provide clear evidence that ApoE plays a critical role in mediating deposition and clearance of Ab 
levels, the mechanisms in doing so remained to be discovered.  
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The other core pathological feature of AD is neurofibrillary tau tangles (NFT). Tau is a 
microtubule-associated protein that plays an important role in microtubule assembly and 
stabilization, necessary for neuronal morphology and structure, transportation of vesicles and 
organelles, and an anchor for enzymes (Yipeng Wang and E Mandelkow, 2015). The structure of 
tau has a proline-rich region with two domains on each end: a basic assembly domain on the C-
terminal and an acidic projection domain on the N-terminal (Mukrasch et al., 2009). The opposing 
charges on opposite ends of tau are crucial for interactions between microtubules as well as for 
internal folding and aggregation (E-M Mandelkow and E Mandelkow, 2012).  
An important characteristic of tau is the large number of potential phosphorylation sites. 
Maintaining balance between phosphorylation and dephosphorylation under physiological 
conditions is critical (Johnson and Stoothoff, 2004). Under normal conditions, tau phosphorylation 
promotes microtubule assembly and axonal transport (Johnson and Stoothoff, 2004). Several 
phosphatases interact with tau to reverse phosphorylation, including protein phosphatase 1 (PP1), 
PP2A, PP2B, and PPC (Tian and Jianzhi Wang, 2002). The conversion of normal tau into paired 
helical filaments (PHF, the main component of NFT) occurs when specific combinations of 
Ser/Thr kinases (cdk5/GSK3 and calcium calmodulin kinase II/GSK3b) hyperphosphorylate 
within the proline-rich segment of tau (KL Rosenberg et al., 2008). This state can be reversed by 
PP2A, which has the ability to dephosphorylate tau, preventing its assembly into PHFs, and 
allowing it to bind back to microtubules. Alternatively, if different combinations of protein kinases 
rephosphorylate tau, then the PHF will lead to NFT formation associated with AD (Jian Zhi Wang 
et al., 2007). Hyperphosphorylated tau is resistant to degradation and prone to aggregation leading 
to NFT.  
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An addition to hyperphosphorylated tau, NFT are composed of truncated tau proteins that 
exhibit different conformational properties compared to normal tau. Truncated tau can result in 
abnormal microtubule assemblies leading to neuronal toxicity (Zilka et al., 2006). Normal 
posttranslational modifications involve the cleavage of tau by caspases and calpain. (Jian Zhi 
Wang et al., 2007). However, tau can become prone to hyperphosphorylation when abnormal 
cleaving events occur. One suggestion is that when tau is cleaved at its N-terminus by calpain, it 
becomes susceptible for caspase to cleave tau at its C-terminus resulting in toxic truncated tau 
(Jian Zhi Wang et al., 2007). In AD brain tissue, caspases associated with these tau cleavage events 
(caspase 823 and caspase924) are co-localized with NFT (Rohn et al., 2002). The development of 
these altered posttranslational modification events leading to truncated tau remain to be 
discovered.  
There are no clear answers to describe the interaction between NFT and Ab. Furthermore, 
mutations and abnormalities in tau are not specific to AD. Tau is located on chromosome 17 and 
specific mutations in this gene (FTDP-17) are linked to frontotemporal dementia with 
parkinsonism resulting in abnormally phosphorylated tau pathology with no amyloid pathology 
(Baker et al., 1997; Hutton et al., 1998; Spillantini et al., 1998; Poorkaj et al., 1998). However, 
studies have observed indications of one pathology influencing the other. Specifically, in mice 
overexpressing a mutant form of tau commonly used to study tauopathies (a general term for 
neurodegenerative disorders that involve the aggregation of tau protein into NFT), injection of 
Ab42 peptides result in elevated hyperphosphorylated tau (Gotz et al., 2001). Analogously, AD 
mice expressing mutations in both APP and tau display tau pathology earlier compared to mice 
with just the tau mutation (Lewis et al., 2001; M Pérez et al., 2005; Ribé et al., 2005; Terwel et 
al., 2008).  
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One possible link between NFT and Ab points to the actions of a protein kinase called 
glycogen synthase kinase 3 beta (GSK3b). GSK3b impairs the ability of tau to both bind and 
stabilize microtubules (Johnson and Hartigan, 1999; Cho and Johnson, 2004). Tau becomes 
hyperphosphorylated in GSK3b-overexpressing mice (Engel et al., 2006). PS1 mutation (one of 
the mutations in familial AD associated with altered Ab processing) can increase GSK3b activity 
and its association with motor proteins on microtubules that interact with tau, leading to 
dissociation of tau with microtubules and the possibility to aggregate (Pigino et al., 2003). Various 
AD transgenic animal models and in vitro studies (targeting either mutations in APP, tau, or both) 
display increased GSK3b activity (Takashima et al., 1996; 1998; Ishizawa et al., 2003; Billings et 
al., 2007; Terwel et al., 2008). In vivo and in vitro AD model studies also demonstrate that 
inhibition of GSK3b attenuates APP processing and reduces hypersphosphorylated tau (Phiel et 
al., 2003; Noble et al., 2005). A more recent study compared the interaction of single nucleotide 
polymorphisms (SNPs) associated with the GSK3b gene with postmortem AD pathologies and 
found interactions between SNPs and both Ab plaques and NFT (Hohman et al., 2016). The 
authors suggest that Ab and NFT progression may be independent and that GSK3b activity is the 
point at which the pathologies intersect.  
The progression of NFT and hyperphosphorylated tau in AD follows a distinct neurological 
pattern that begins in the entorhinal cortex (Braak stages I-II), spreads the limbic and adjoining 
neocortex (stages III-IV), then to the neocortex including the secondary and primary fields (stages 
V-VI) (H Braak and E Braak, 1991; Bancher et al., 1993; H Braak and E Braak, 1997; H Braak et 
al., 2006). The degree of NFT formation in postmortem AD brains and the progression through 
the Braak staging is strongly correlated with increasing memory loss and dementia (H Braak and 
E Braak, 1991; 1997). Since the limbic system, particularly the hippocampus, is involved in 
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memory systems, Braak staging correlates the memory deficits associated with AD. Other 
pathologies follow a similar pattern of neurological pattern referred to as Braak staging, including 
Ab plaques, reactive microglia, and cholinergic loss (Serrano-Pozo et al., 2011). However, 
compared to Ab oligomers and plaques, some researchers believe that the NFT are the main source 
of cognitive decline in patients with AD (Wilcock and Esiri, 1982; Delaère et al., 1989; Arriagada 
et al., 1992; Duyckaerts et al., 1997; Gómez-Isla et al., 1997; Delacourte et al., 2002; 
Giannakopoulos et al., 2003; Guillozet et al., 2003; Bretteville and Planel, 2008). Animal models 
with tau mutations corroborate these findings, demonstrating significant impairment in learning 
and memory and altered hippocampal synaptic plasticity (Polydoro et al., 2009; Hoover et al., 
2010; Van der Jeugd et al., 2011; Burnouf et al., 2012).  
Lastly, cholinergic cell loss is commonly found in postmortem analysis of AD brains and 
is the another core feature of the disorder. The pattern of cell loss follows a similar progression to 
the Braak staging discussed previously (Beach et al., 2000). Additional evidence towards 
disruptions in acetylcholine signaling are associated with the reduction in acetyltransferase (the 
enzyme that modulates production of acetylcholine) and acetylcholinesterase (the enzyme that 
degrades acetylcholine) (Davies, 1979). It is unclear how cholinergic changes are brought about 
and has been the focus of considerable research. Most of the currently available drug therapies for 
AD target the cholinergic system by inhibiting acetylcholinesterase. Although these drugs can slow 
the progression of symptoms in patients with mild cases of AD, they do not halt the disorder 
(Rogers et al., 1998; Rösler et al., 1999; Birks, 2006).        
Many transgenic mouse models of AD exist to help researchers understand the disease 
progression. They have been exceedingly useful in highlighting signaling mechanisms and protein 
interactions related to the disorder; however, no single transgenic model represents all aspects of 
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the disease spectrum. The most common class of transgenic mice are those overexpressing human 
mutations in APP. These animals typically develop Ab plaques composed of Ab42 between 6-9 
months of age (LaFerla and KN Green, 2012). They also develop memory impairments that can 
be observed before the appearance of plaques, suggesting that Ab may be mediating cognitive 
decline (LaFerla and KN Green, 2012). Based on data from transgenic mice, researchers 
discovered that Ab oligomeric species may play a larger role in the pathogenicity of AD (Haass 
and Selkoe, 2007). Interestingly, NFT are not observed in APP-overexpressing mice, yet some 
display hyperphosphorylated tau (Götz et al., 2007). Several reasons may account for the lack of 
NFT, including rodent tau having a different structure that prevents it from accumulating into NFT 
or another possibly is that the rodent’s lifespan is not long enough to allow for the development of 
NFT which takes decades in humans. To account for the lack of NFT, multigenic mice were created 
that have mutated human tau in addition to overexpression APP (Lewis et al., 2001; Oddo et al., 
2003). Sophisticated transgenic mouse models have since been generated, incorporating a variety 
of known genetic mutations to mirror AD pathologies. In addition to the core pathologies, most of 
these models exhibit cognitive decline and increased neuroinflammation (LaFerla and KN Green, 
2012). They have revealed discoveries of potential disease progression and interactions not 
previously considered.   
Translational issues exist with the vast majority of transgenic models used to recapitulate 
AD pathologies, since nearly all are mutations associated with APP processing or tau (or both). 
However, these mutations reflect those found in familial AD and not what is observed with 
sporadic AD, which is far more prevalent. Although useful in advancing our understanding of the 
disorder, concerns arise with using transgenic AD models to examine new therapeutics or targets 
slated for the heterogeneous human AD population and may contribute to the lack of consistency 
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between results in preclinical trials and human clinical trials (LaFerla and KN Green, 2012). Using 
animal models that exhibit known risk factors associated sporadic AD to examine drug therapies 
would be a beneficial translational approach. 
Diabetes Risk Factor 
 Individuals with diabetes have an increased risk of developing AD (Brands et al., 2005; 
Biessels et al., 2006). Diabetes is a metabolic disorder that results in hyperglycemia and insulin 
dysregulation. Currently, 80% of patients diagnosed with AD have impairments in glucose 
tolerance or have been diagnosed with diabetes (Janson et al., 2004). Approximately 23.6 million 
people in the United States are affected by diabetes, with this number predicted to increase to over 
29 million by 2050 (Centers for Disease Control, 2014). Between 5-10% of these individuals have 
Type 1 diabetes, characterized by hyperglycemia and insulin deficiency. Whereas the most 
common form is Type 2 diabetes, accounting for 90-95% of cases and is associated with 
hyperinsulinemia and insulin resistance. Mild to severe cognitive impairments are associated with 
both forms of diabetes, including memory impairments and attention (Strachan et al., 1997; Awad 
et al., 2004). Individuals with Type 2 diabetes are twice as likely to develop AD later in life 
compared to the normal population (Janson et al., 2004), while Type 1 diabetes patients have an 
80% chance of being diagnosed with AD (Whitmer et al., 2015). Due to the heterogeneity of 
diabetes symptoms, it is difficult to determine which component contributes to the risk associated 
with developing AD.  
 Evidence exists that suggest insulin resistance may be a contributing factor in AD. Insulin 
is produced by pancreatic beta cells and regulates glucose metabolism in the periphery (Woods et 
al., 1985; Saltiel and Kahn, 2001). Early studies of brain glucose metabolism considered the brain 
as insulin insensitive, since the uptake of glucose by the CNS is not dependent on insulin. The 
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transportation of glucose into neurons and glia relies on GLUT3 and GLUT1 receptors (McEwen 
and Reagan, 2004; Gray et al., 2014). However, it has since been discovered that CNS insulin 
levels regulate overall energy homeostasis as well as control of food intake, metabolic rate, and 
energy expenditure (Schwartz et al., 1992; Chavez et al., 1995). In addition, insulin concentration 
in the brain is independent of circulating peripheral insulin (Havrankova et al., 1979), yet insulin 
readily crosses the blood brain barrier via an insulin receptor-mediated transport process (Baskin 
et al., 1987; Baura et al., 1993; Banks, Jaspan, Huang, et al., 1997; Banks, Jaspan, and Kastin, 
1997). Evidence suggests that insulin is produced locally in the brain, as insulin CNS 
concentrations are 10-100 times higher compared to plasma levels (Havrankova, Roth, et al., 
1978); however, further investigations are needed to elucidate the mechanisms of its local 
production.  
Receptors for insulin are selectively distributed in the brain, with the highest density found 
in the olfactory bulb, hippocampus, amygdala, cerebral cortex, and hypothalamus (Havrankova, 
Schmechel, et al., 1978; Havrankova, Roth, et al., 1978; Baskin et al., 1987; Unger et al., 1991). 
Both neurons and astrocytes express insulin receptors located at the synapses (Abbott et al., 1999). 
Due to their abundance in the hippocampus and areas of the medial temporal cortex, insulin and 
insulin receptors play a role in modulating synaptic activity, LTP, and memory (Baskin et al., 
1988; W-Q Zhao and Alkon, 2001). For instance, insulin influences cell membrane expression of 
N-methyl-D-aspartate (NMDA) receptors, which are highly abundant in these regions and are 
critical for LTP and synaptic plasticity (Skeberdis et al., 2001).  
Memory enhancement after insulin administration has been observed in several studies. 
Rodent studies have found enhanced memory performance in the Morris water maze and passive-
avoidance task after intracerebroventricular insulin infusions (Park et al., 2000; Haj-ali et al., 
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2009). In healthy humans, intranasal and intravenous administration of insulin enhances story 
recall and improvement in cognitive flexibility (Kern et al., 1999; Craft et al., 1999; Fehm et al., 
2000). Similarly, studies demonstrate that insulin receptor expression can be modulated by 
learning. In one study, insulin signaling molecules and the amount of insulin receptor mRNA in 
the hippocampus was increased in rats trained in the Morris water maze compared to untrained 
rats (W Zhao et al., 1999).  
In AD, low concentrations of insulin and an increase number of insulin receptors are 
observed compared to age-matched controls (Frölich et al., 1999; Hoyer, 2002; Craft and Watson, 
2004). Dysregulation of cellular processes related to insulin are thought to contribute to both AD 
and type 2 diabetes, including glucose and cholesterol metabolism, ApoE processing, and second 
messenger signaling (Janson et al., 2004; Martins et al., 2006; Moreira et al., 2007; W-Q Zhao 
and Townsend, 2009). It is further speculated that insulin dysregulation in AD exacerbates the 
formation of Ab plaques and NFT (Sims-Robinson et al., 2010). One theory suggests that altered 
insulin signaling results in chronic oxidative metabolism and increased acidosis in the Golgi 
apparatus and endoplasmic reticulum that alter APP metabolism, resulting in a favorable 
atmosphere for the accumulation of Ab (Frölich et al., 1999; Hoyer, 2002).  
Insulin and Ab are both degraded by insulin-degrading enzyme (IDE) in healthy neurons 
and microglia. In type 2 diabetes, insulin resistance results in elevated insulin levels potentially 
leading to competition between Ab and insulin for IDE (Gasparini and H Xu, 2003). Brain tissue 
from AD patients display significantly lower amounts of IDE mRNA compared to age-matched 
controls (A Pérez et al., 2000; Cook et al., 2003; Farris et al., 2003). Thus, a deficiency in IDE 
processing may contribute to pathologies in AD and diabetes. In a study examining the effects of 
insulin on Ab42 levels in CSF of healthy older adults, researchers found that intravenous insulin 
 
 
 
16 
administration led to an increase of Ab42 in the CSF (Watson et al., 2003). As mentioned 
previously, insulin infusions lead to enhanced memory abilities but this effect was decreased in 
older individuals with the greater increase in CSF Ab42 concentrations. The clearance mechanisms 
of Ab42, potentially via IDE, may be disrupted in older adults as a consequence of age and the 
sustained elevation of Ab42 may affect memory (Craft and Watson, 2004). Insulin sensitizers may 
aid in alleviating competition between insulin and Ab with IDE by increasing the sensitivity of 
insulin receptors (Pedersen et al., 2006). AD transgenic mice treated with the insulin sensitizer, 
rosiglitazone, had reduced Ab42 levels and improvement in spatial learning and memory 
(Pedersen et al., 2006). A preliminary study using rosiglitazone in AD patients resulted in better 
cognitive measures after treatment versus before; however, no change or decline in Ab42 levels 
were observed (Watson et al., 2005). Together, insulin dysregulation influences Ab levels 
potentially via IDE. 
In vitro and in vivo studies demonstrate that insulin regulates tau phosphorylation (M Hong 
and VM-Y Lee, 1997; Lesort and Johnson, 2000; Schubert et al., 2003; Cheng et al., 2005). 
Conversely, hyperinsulinemia occurs following tau hyperphosphorylation in rat brains (Freude et 
al., 2005). Furthermore, mice deficient in insulin receptor substrate-2 (Schubert et al., 2003; 2004) 
or the neuronal insulin receptor gene (Schubert et al., 2004) result in increased tau phosphorylation 
and NFT. Intranasal insulin has been shown to ameliorate tau hyperphosphorylation in a rodent 
model of type 2 diabetes (Yang et al., 2013). Despite observing changes in phosphorylated states 
of tau in culture and animal models of diabetes, little is known about diabetes and tau pathogenesis.  
Mitogen-activated protein kinase (MAPK) and Akt-signaling pathways (both implicated in 
AD pathogenesis) are cellular mechanisms activated after insulin receptor signaling. MAPK is 
ubiquitous kinase that regulates cell proliferation and cell death (Pearson et al., 2001). MAPK 
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immunoreactivity and expression is increased in AD brains compared to normal controls (Hensley 
et al., 1999) and is correlated with Ab plaques and NFT (Hensley et al., 1999; Munoz and Ammit, 
2010). Further, studies have demonstrated its involvement in tau phosphorylation, 
neuroinflammation, and synaptic plasticity (Munoz and Ammit, 2010). Akt signaling mediates cell 
proliferation and protein synthesis (Brazil and Hemmings, 2001; Tremblay and Giguère, 2008). 
Through Akt signaling, insulin receptor activation via insulin leads to GSK3b inactivation. 
Changes in glucose and insulin concentrations in the hippocampus and cortex influences GSK3b 
activity (Clodfelder-Miller et al., 2005). During insulin resistance, GSK3b is dephosphorylated 
and, thus, activated (Clodfelder-Miller et al., 2006); (Balaraman et al., 2006). Activation of 
GSK3b can further perpetuate insulin resistance by reducing glucose clearance (J Lee and Kim, 
2007), increased PS1 activity leading to elevation in Ab production (Phiel et al., 2003), and 
hyperphosphorylated tau (Balaraman et al., 2006). 
The association between AD and diabetes is particularly strong among APOE e4 carriers 
(Kuusisto et al., 1997; Peila et al., 2002; Irie et al., 2008; Matsuzaki et al., 2010). For example, 
ApoE4 carriers with type 2 diabetes have a five-fold risk of developing AD compared with 
individuals who are not ApoE4 carriers and do not have diabetes (Haan, 2006). The prevalence of 
Ab plaques and NFT are greater in patients with diabetes who have ApoE4 and insulin 
dysregulation in some patients with sporadic AD to has been linked to the APOE genotype (Peila 
et al., 2002).  
Clinical trials examining effect of intranasal insulin as potential therapy in early AD are 
ongoing. Insulin can bypass the blood-brain barrier and enter the CSF via intranasal administration 
(Born et al., 2002). Studies on older adults with AD or mild cognitive impairment showed 
significant improvement in memory with both low and high doses of intranasal insulin that 
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persisted two months after the end of treatment (Craft, 2012; Yarchoan and Arnold, 2014). 
Although acute intranasal insulin treatment shows promise with cognitive functioning, long-term 
studies are imperative to ensure that hyperinsulinemic conditions do not promote further insulin 
resistance in AD patients.  
A commonly used method to study diabetes and AD pathologies in rodents uses the 
administration of a compound called streptozotocin (STZ; 2-deoxy-2-(3-(methyl-3-nitrosoureido)-
D-glucopyranose). STZ is selective for glucose transporter 2 (GLUT2) located mainly on insulin 
producing pancreatic beta cells and results in alkylation and methylation of DNA leading to 
apoptosis (Murata et al., 1999; Szkudelski, 2001). Permanent diabetes results when high doses 
(100-200 mg/kg, intraperitoneal) are administered to rodents, that results in little to no insulin 
production and high mortality rate among subjects (Szkudelski, 2001; Grünblatt et al., 2007). 
Alternatively, multiple low to moderate doses of STZ (30-60 mg/kg, intraperitoneal) results in 
insulin resistance by maintaining insulin-immunoreactive cells in the pancreas (Ito et al., 1999). 
In this animal model of type 1 diabetes, animals display learning deficits (Stranahan et al., 2008), 
increased GSK3b activity (Jope and Johnson, 2004), increased tau phosphorylation, increase Ab 
levels, and neuroinflammation (Mensah-Brown et al., 2005; Jolivalt et al., 2008). Two routes of 
administration are common using STZ: peripheral administration that targets pancreatic beta cells 
and intracerebroventricular (ICV) infusions that results in reduced expression of insulin receptors 
in the brain (Nazem et al., 2015). Both models develop learning and memory impairments in a 
variety of tasks (including Morris water maze, novel object recognition, and Barnes maze), AD 
pathologies, and elevated neuroinflammation (Šalković-Petrišić et al., 2011; Nazem et al., 2015; 
Murtishaw et al., 2016; Murtishaw et al., in review). When STZ is administered to APP transgenic 
mice, induction of diabetes exacerbated AD symptoms including learning deficits, increased tau 
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phosphorylation, increase number of Ab plaques, increased GSK3b activity, and decreased insulin 
receptor activity (Jolivalt et al., 2010). Thus, STZ administration provides researchers with a 
translational approach to examine sporadic AD that encompasses the risk factor diabetes.  
A strong link exists between AD and diabetes, yet both disorders occur on a spectrum and 
exhibit heterogeneity in their symptomology. A feature related to both disorders that may play a 
role in exacerbating AD pathologies is chronic neuroinflammation. Determining the relationship 
between AD, diabetes, and neuroinflammation is vital to providing effective treatment in AD.   
Neuroinflammation Risk Factor 
Inflammation is a complex process that occurs in response to injury, infections, or threats 
that restores the body back to normal physiology. The CNS has a specialized immune system due 
to the protective blood-brain barrier and this system involves complex orchestrations across many 
neuronal and non-neuronal cell types (Burda and Sofroniew, 2014). The principal responders to 
damage to the CNS are glial cells (primarily microglia, oligodendrocytes, and astrocytes), which 
preserve homeostasis to allow neurons to function normally. An alteration in glial cell function 
can greatly impact neuronal synchrony and overall CNS function. Reactive gliosis, the nonspecific 
reaction glial cells to damage in the CNS, can take on different forms depending on the type of 
injury, insult, or even disease state (Sofroniew and Vinters, 2009; Burda and Sofroniew, 2014). 
Various cells types are involved in reactive gliosis that respond in different ways to an array of 
insults. For instance, acute insults initiate tissue replacement and would repair, while disperse and 
chronic diseases trigger progressive tissue changes (Burda and Sofroniew, 2014). 
Neuroinflammation is a state of chronic, sustained inflammatory response which can persist long 
after the initial injury (Z Cai et al., 2014). 
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Reactive gliosis and subsequent sustained neuroinflammation is a dynamic, complicated 
process in neurodegenerative disorders. Although many cells types and factors are involved, 
microglia have been the primary focus in AD inflammation research, as their function appears to 
be dysregulated in the disorder. Microglia serve as the main resident immune cells, making up 10 
to 15% of total cells in the CNS. These phagocytic macrophages circulate or “survey” the 
environment where they are uniformly distributed and provide signals that influences astrocytes 
and neurons (Z Cai et al., 2014). During normal, physiological conditions, microglia exhibit a 
deactivated or ramified state where they release anti-inflammatory cytokines and neurotrophic 
factors and regulate synaptic plasticity (Streit, 2002). They also participate in removing debris 
from non-neuronal apoptotic cell death (Schafer and Stevens, 2015).  
In response to injury or invasion, adenosine triphosphate dependent mechanism attracts 
microglia to the site of injury where the microglia initiate repair functions (Davalos et al., 2005; 
Haynes et al., 2006). They switch to a reactivate (or primed) state and change their chemical and 
morphological structure. Their normally protracted filopodia that allows them to monitor synaptic 
activity retract and they take on more of an amoeboid structure, compromising microglial 
regulation of network homeostasis (Van Eldik et al., 2016). They become fully phagocytic and 
release a variety of factors including pro-inflammatory cytokines, free radicals, and neurotoxins 
(Wierzba-Bobrowicz et al., 2002). The types of cytokines released and alterations of gene 
expression classify microglia generally as classically activated (M1) or alternatively activated 
(M2). M1-polarized microglia are poor phagocytes that release pro-inflammatory cytokines, 
including tumor necrosis factor - a (TNFa), interleukin (IL)-1, IL-6, IL-12, IL-18, nitric oxide, 
and prostaglandins (Malm et al., 2015). Alternatively, high phagocytosis capabilities and secretion 
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of anti-inflammatory cytokines, such as IL-10, IL-4, IL-13, and transforming growth factor-b, are 
a feature of M2-polarized microglia (Malm et al., 2015).  
Ab, NFT, and neuronal cell loss are perhaps stimulants of microglia in the AD brain. In 
the presence of Ab, microglia release chemokines (specifically C-C chemokine ligand 2) (Boddeke 
et al., 1999), which attract other microglia. In AD patients and transgenic AD mice, levels of C-C 
chemokine ligand 2 (CCL2) are increased (Oddo et al., 2003; Jankowsky et al., 2004; Janelsins et 
al., 2005) and mice that do not express its receptor (CCR2) have microglial impairments in being 
recruited to the site of Ab plaques as well as higher levels of Ab (Khoury et al., 2007; Naert and 
Rivest, 2011). A variety of cell surface recognition receptors allow microglia to detect fibrillary 
forms of Ab, including Toll-like receptors (TLRs) 2, 4, and 6, cluster of differentiation (CD) 14, 
CD 36, A1 scavenger receptors (SCARA1), and class B2 scavenger receptors (Coraci et al., 2002; 
Khoury et al., 2003; Frenkel et al., 2013). After stimulation of these receptors, various signal 
transduction pathways are activated that lead to nuclear factor kappa B (NF-kB)-dependent 
transcription of pro-inflammatory cytokines , reactive oxygen species, and phagocytosis (DR 
McDonald et al., 1998; Bamberger et al., 2003; Alarcón et al., 2005; Fang et al., 2010; Heneka et 
al., 2012). The pathophysiology of diabetes also implicates increased phosphorylation of NF-kB 
and subsequent increase in pro-inflammatory cytokines (Negi et al., 2010; Yirmiya and Goshen, 
2011; Datusalia and SS Sharma, 2014). At this point in the signaling pathway, these responses can 
have both advantageous and deleterious effects. For example, enhanced expression of SCARA1 
aids to clear Ab (Frenkel et al., 2013). Conversely, mediates pro-inflammatory production, of 
which has detrimental effects.  
Enhanced expression of pro-inflammatory cytokines have been found in AD and diabetes 
brain and CSF, including TNFa, IL-6, IL-10, and IL-1b (Blum-Degen et al., 1995; Tarkowski et 
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al., 2002; Mrak and Griffin, 2005b; H Jiang et al., 2011; Yirmiya and Goshen, 2011; Datusalia 
and SS Sharma, 2014). Chronic released of pro-inflammatory cytokines by microglia increase the 
production of Ab by favoring the toxic cleavage of APP towards g- and b- secretase (Blasko et al., 
2000; HS Hong et al., 2003; Liao et al., 2004; Malm et al., 2015). Moreover, chronic inflammation 
reduces the levels of IDE and the phagocytic capability of microglia, further perpetuating Ab 
accumulation (Chung et al., 1999; Koenigsknecht-Talboo and Landreth, 2005; Rezai-Zadeh et al., 
2011). Reactive microglia are initially beneficial to the system in response to a harmful stimulus; 
however, chronic reactive responses may amplify destructive effects.  
While the removal of these toxins is initially advantageous, a wealth of evidence 
demonstrates that the upregulation of certain immune system components may result in further 
neurodegeneration more destructive than the initial pathogenic stimulants (Akiyama et al., 2000). 
AD is a very slow process that may span 20 years between initial Ab accumulation to the 
appearance of cognitive deficits (Villemagne et al., 2013). Increased pro-inflammatory cytokines 
can increase Ab deposition and deficits in learning and memory (Games et al., 1995; Wyss-Coray 
and Mucke, 2002; Guo et al., 2002; Wyss-Coray, 2006). In a study examining P301S mutant 
human tau transgenic mice, activated microglia were detected early in neurodegeneration link tau 
abnormalities and microglia (Yoshiyama et al., 2007). Activation of inflammatory markers (TNF-
a and monocyte chemoattractant protein-1) was observed in triple transgenic (overexpressing 
APP, PS1, and tau mutations) AD mice as early as three months of age and occur alongside the 
accumulation of Ab (Janelsins et al., 2005). In cell culture studies, IL-6 and IL-1 amplify levels of 
tau hyperphosphorylation and NFT (Yuekui Li et al., 2003; Quintanilla et al., 2004; Saez et al., 
2004). As mentioned in the previous chapter, non-transgenic AD models using the diabetes risk 
factor display increased neuroinflammation. Animals given STZ exhibited increased IL-1 and 
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TNF-a in addition to microglial activation (Prickaerts et al., 1999; Y Chen et al., 2013; Murtishaw 
et al., 2016). Therefore, neuroinflammation enhances AD pathologies in postmortem brain tissue 
and animal models of AD.  
Inflammation associated with AD was initially thought to occur during end stages of the 
disorder and did not contribute to the progression of symptoms. However, data from genetic, 
preclinical, and bioinformatics studies reveal that the immune system not only accompanies but 
contributes to AD symptoms (Zhang et al., 2013). A current hypothesis implicates microglia as 
the main facilitator in neuroinflammation that contributes to and progresses AD pathology (Zheng 
et al., 2010). The most compelling research to date that links microglia with AD progression comes 
from genome-wide association studies (GWAS) in a which rare variants of several genes 
associated with microglia has been identified as a risk factors for sporadic AD (Guerreiro et al., 
2013; Jonsson et al., 2013; Bertram et al., 2013; Benitez et al., 2013; Ruiz et al., 2013; Slattery et 
al., 2014). A rare missense mutation associated with TREM2, a transmembrane receptor found in 
various tissue macrophages including microglia and bone marrow-derived macrophages, is one 
such risk factor (Daws et al., 2001; Paloneva et al., 2002; Schmid et al., 2002). Overexpression of 
TREM2 on microglia in vitro increases its ability to clear Ab (Melchior et al., 2010; T Jiang et al., 
2014) and attenuate the release of pro-inflammatory cytokines (K Takahashi et al., 2005; Turnbull 
et al., 2006; Hamerman et al., 2006). Microglia are commonly found near Ab plaques in AD mouse 
models; however, in TREM2-deficient mice, microglia are absent from Ab plaques (Ulrich et al., 
2014; Yaming Wang et al., 2015). Additional studies found that TREM2 reduces microglial 
phagocytic function and pro-inflammatory response in the presence of Ab (Hickman and Khoury, 
2014; Kleinberger et al., 2014). Another risk factor for AD discovered from GWAS is associated 
with increased CD33 expression in microglia and monocytes (Van Eldik et al., 2016). The 
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increased expression of CD33 is suggested to promote Ab42 accumulation (Griciuc et al., 2013; 
Bradshaw et al., 2013; Malik et al., 2013). As discussed in previous chapters, the ApoE4 is another 
risk factor associated with AD discovered through GWAS. Studies in microglia provide evidence 
that ApoE4 is less efficient at promoting enzyme-mediated clearance of Ab compared to ApoE3 
(Q Jiang et al., 2008). Independent of Ab, ApoE4 activate an inflammatory response that leads to 
the breakdown of the blood-brain barrier and leakage of microvasculature that releases toxic 
proteins into the brain (Bell et al., 2012). These risk factors provide a crucial link between 
microglia, Ab clearance, and sporadic AD.   
Early epidemiological studies found that individuals with arthritis had a lower rate of 
developing AD and this observation has since been correlated with the use of nonsteroidal anti-
inflammatory drugs (NSAIDs) (McGeer et al., 1990). Follow-up studies have reported that there 
is a 50% reduction in the risk of developing AD for those who are long-term users of NSAIDs 
(Wyss-Coray, 2006). The main targets of NSAIDs are cyclooxygenase (COX-1) and COX-2 where 
they act by inhibiting key inducers of inflammation (prostaglandins and thromboxanes) (Wyss-
Coray, 2006). With respect to AD, alternative targets of NSAIDs have been examined including 
peroxisome proliferator-activated receptor-g (PPAR-g) and the presenilins. In cell culture, PPAR-
g reduces Ab levels by inhibiting the activity of b-secretase cleaving enzyme 1 (BACE1) promotor, 
which the enzyme that metabolizes APP into the pathogenic form (Sastre et al., 2006). Studies 
using cell culture and APP transgenic mice have found reductions in Ab levels with different 
NSAIDs that have varying affinity for COX and alternative targets (Weggen et al., 2001; Eriksen 
et al., 2003; Y Takahashi et al., 2003; Lleó et al., 2004; Beher et al., 2004; Gasparini et al., 2004). 
One particular NSAIDs (R-flurbiprofen or Flurizan™) did exceptionally well in Phase I and II 
trials, where it slowed functional and cognitive decline in AD patients for up to 21 months of 
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treatment yet failed to show any beneficial changes in several Phase III trials (RC Green et al., 
2009). Overall, these studies suggest that the downstream targets of NSAIDs may be acting upon 
Ab or Ab precursors but not necessarily on directly reducing inflammation that is chronically 
activated in AD.  
As mentioned, microglia respond to and proliferate towards chemokines. The soluble form 
of a chemokine, called fractalkine or CX3CL1, mediates microglial chemoattraction 
(Maciejewski-Lenior et al., 1999). Exogenous application of CX3CL1 results in increased 
microglial proliferation, as they express the fractalkine receptor CX3CR1 (Hatori et al., 2002). 
Insufficient signaling of CX3CL1/R1 leads to an enhanced microglial inflammatory response, as 
demonstrated by mice lacking functional CX3CR1 receptors (Cardona et al., 2006). For example, 
APP/PS1 mice lacking functional CX3CR1 showed increased levels of TNFa and IL-1b (S Lee et 
al., 2017). Methods to reduce chronic microglia proliferation in AD models would be useful to 
understanding the disorder. In particular, baclofen (a GABAB receptor agonist) has been found to 
reduce pro-inflammatory cytokine release in peripheral leucocytes that express CX3CR1 (Duthey 
et al., 2010) and microglia cell cultures (Kuhn et al., 2004). Not only can GABAB receptors lead 
to inhibition of microglia via the neurotransmitter GABA but it has suggested that they can also 
interfere with microglial chemotaxis through chemokine receptors (Duthey et al., 2010). 
Therefore, outlining the role of GABAB inhibition on microglia may aid in our understanding of 
neuroinflammation in AD.  
 
GABAB Signaling in Alzheimer’s Disease and Neuroinflammation 
Multiple neurotransmitter systems are implicated in the progression of AD, including 
acetylcholine, dopamine, glutamate, monoaminergic systems, and GABA (Francis et al., 1999; 
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Iwakiri et al., 2005; Yanfang Li et al., 2016). However, GABA signaling on microglia may serve 
a role in reducing neuroinflammation and subsequently halt the progression of AD symptoms.  
  Gamma-aminobutryic acid (GABA) the main inhibitory neurotransmitter in the brain and 
is synthesized from glutamate in neurons expressing glutamic acid decarboxylase (GAD). Two 
main classes of GABA receptor systems exist: GABAA and GABAB. GABAA receptors are 
ionotropic and permeable to chloride. Activation of these receptors leads to a quick-onset 
hyperpolarization (Macdonald and Olsen, 1994). GABAB receptors are metabotropic Gi/Go 
coupled receptors located pre- and postsynaptically (Bettler et al., 2004), where they function to 
regulate ion channels by either activating potassium channels or inhibiting calcium channels 
(Gassmann and Bettler, 2012). Furthermore, GABAB receptor modulates GABA and glutamate 
neurotransmitter release and reduces depolarization induced by excitatory neurotransmitters 
(Bettler et al., 2004). In neurons, GABAB plays a large role in regulating oscillatory activity 
necessary for cognition and learning and memory (Gaiarsa et al., 2011).  
A growing body of literature illustrates the role of GABA in regulating inflammatory 
responses and suggests that GABA induces a neuroprotective phenotype in microglia (Mead et al., 
2012). Microglia express functional GABAB receptors in culture and in vivo (Kuhn et al., 2004; 
Liu et al., 2016). Studies demonstrate that microglia can modulate pro-inflammatory cytokine 
release in response to GABA concentrations. For example, GABAB receptor agonists activate 
outward rectifying potassium channel conductance in microglia and reduce the release of pro-
inflammatory cytokines IL-6 and IL-12p40 (Kuhn et al., 2004). Furthermore, GABAB receptors 
are increased on microglia in response to injury (Kuhn et al., 2004). As mentioned in the previous 
chapter, GABAB receptors might be able to alter chemotaxis of microglia. For example, baclofen 
reduces the migration of CX3CR1 containing peripheral blood monocytes towards CX3CL1 by 
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70% (Duthey et al., 2010). CX3CR1 are also G protein coupled receptors. It is proposed that the 
Gi protein associated with GABAB receptors may interfere and inhibit the function of pro-
inflammatory CX3CR1 linked to the Gi signaling pathway through heterologous desensitization 
(Duthey et al., 2010). Taken together, GABAB receptors may serve to regulate microglia activity 
in times of stress.    
In AD, GABAergic signaling undergoes profound pathological changes in AD resulting in 
decreased neurotransmission and neuronal receptor expression (Iwakiri et al., 2005; Yanfang Li et 
al., 2016). Conflicting data exist over the altered expression of various GABAA receptor subtypes 
in brain samples from AD patients (Yuan and Shan, 2014). However, a correlation exists between 
the reduction GABAB receptor expression and AD pathologies in AD brains (Iwakiri et al., 2005).  
Together these data suggest that a reduction in GABAergic tone in AD may compromise 
an important anti-inflammatory pathway via GABAB receptor function on microglia and possibly 
exacerbate progression of AD. As of yet, there are no studies outlining the effect of GABAB 
receptors on microglia in AD.  
Experimental Hypotheses and Implications 
 The purpose of this study is to examine the role of GABAB receptors on neuroinflammation 
in a rodent model of sporadic AD that encompasses the diabetes risk factor. A considerable amount 
of data exists examining AD pathologies in transgenic rodent models. However, these models 
recapitulate genetic manipulations that are only observed in familial AD patients (1-5% of AD 
population). Inducing a diabetic-like state in an animal model that displays AD pathologies and 
neuroinflammation is a valid, translational approach in examining mechanisms of the disorder.  
 Since it has been demonstrated that GABAB receptor activation on microglia reduces pro-
inflammatory cytokines and neuroinflammation, we propose to investigate their role in a diabetes 
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animal model of AD examining behavior and brain tissue. To induce a diabetic-like state, we 
administered STZ at 40 mg/kg (intraperitoneal) to C57BL/6J mice using a staggered protocol 
similar to the schedule of administration from our laboratory that results in sustained, elevated 
blood glucose levels with zero mortality (Murtishaw et al., in review). When mice reached a group 
average of 250 mg/dL blood glucose level (indicative of a diabetic state; (Atkinson, 2011), the 
GABAB receptor agonist (baclofen, 2 mg/kg, intraperitoneal) administration began. This dose was 
selected based on previous behavioral experiments in our laboratory as well as studies indicating 
that baclofen can induce lethargy, significantly decrease muscle tone, and alter eating behavior at 
higher doses (Patel and Ebenezer, 2010; Heaney et al., 2012; Heaney and Kinney, 2016). Baclofen 
was administered for two weeks, twice a day to ensure that the drug is chronically activating 
GABAB receptors. It should be noted that pancreatic beta cells contain GABAB receptors which 
are involved in insulin production and studies demonstrate that baclofen produces an increase in 
insulin release in these cells (Brice et al., 2002). Although baclofen may enhance the efficiency of 
remaining pancreas beta cells, it cannot reverse the effects of STZ-induced pancreatic beta cell 
death.  
Behavioral tests commenced after a drug washout period to make certain that active 
baclofen will not contributing to behavior. The open field test was performed to examine anxiety 
phenotypes. To assess learning and memory, exploratory behavior in the novel objection 
recognition test (NOR) was measured. Animal models of AD consistently show deficits in 
exploring novel objects in this task, suggesting learning and memory deficits (Antunes and Biala, 
2012; Murtishaw et al., 2016; Murtishaw et al., in review). To investigate associative learning, 
freezing behavior was measured in the cued and contextual fear conditioning test. Components of 
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this task can reveal hippocampal dysfunction (Maren et al., 2013), the first region of neuronal loss 
in AD (Padurariu et al., 2012). Finally, nociceptive differences were tested in the tail flick test. 
 To investigate protein and mRNA changes in the hippocampus and cortex consistent with 
those seen in AD and neuroinflammation, protocols including western blotting, 
immunohistochemistry, and RT-PCR were performed on brain tissue. Targets outlined in Table 1 
were analyzed via western blotting and involve AD related pathological targets (phosphorylated 
tau and Aβ oligomers), a major protein involved in insulin signaling (IDE), and GABAB receptor 
subunits. Activated microglia and microvascular hemorrhages associated with AD were assessed 
via immunohistochemistry. Pro-inflammatory and anti-inflammatory cytokine (outlined in Table 
2) mRNA expression were measured with RT-PCR.  
Hypothesis 1:  
Administration of STZ will lead to behavioral and biochemical changes associated with 
AD.   
 Implications for Hypothesis 1: If administration of STZ leads to behavioral and  
biochemical changes associated with AD, then these data highlight the link between 
insulin dysregulation and its contribution to the progression of AD pathology.   
 Hypothesis 2:  
Chronic activation of GABAB receptors (via baclofen administration) in a diabetes model 
will attenuate neuroinflammation leading to a rescue in behavioral and biochemical 
changes associated with AD.  
 Implications for Hypothesis 2: If deficits in behavior and changes related to AD  
pathology and neuroinflammation in brain tissue induced by STZ administration  
are rescued by chronic baclofen administration, these data would suggest that  
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GABAB receptor activation modulates neuroinflammatory processes.  
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CHAPTER 3 
MATERIALS AND METHODS 
Subjects 
Sample size to determine the number of subjects was calculated a prior using power 
analysis software, G Power (Faul et al., 2007). Using previously collected data our laboratory 
(Murtishaw et al., in review) with power was set at 0.80 and a = 0.05 (two-tailed), sample size 
was calculated at n = 4 per treatment group. To sufficient power for each of the three tissue 
analyses, n = 12 per treatment group was determined (n = 48 total animals used).   
C57BL/6J mice (Jackson Laboratory) were housed six per cage by treatment group (STZ 
or non-STZ). The mouse colony room was on a 12:12 light/dark cycle and mice had access to 
standard chow and water available ad libitum. Behavioral tests were conducted during the light 
cycle. All procedures were approved by the University of Nevada, Las Vegas Institutional Animal 
Care and Use Committee and were performed in accordance with NIH guidelines for the care and 
use of laboratory animals.  
Drugs Treatments 
Mice were randomly assigned to STZ, STZ + baclofen, baclofen alone, or control group (n 
= 12 per group). STZ (Sigma-Aldrich) was prepared immediately before use by dissolving in 
filtered 0.1 M sodium citrate buffer (pH 4.5) for a final concentration of 4 mg/mL, as STZ is 
pharmacologically active for 15 minutes before a fresh batch needs to be prepared (Schein et al., 
1973). Baclofen (Sigma-Aldrich) was dissolved in pharmaceutical grade saline (.9% NaCl) for a 
final concentration of 0.2 mg/mL. 
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Apparatus 
Open Field and Novel Object Recognition Chamber 
 Plexiglas chambers (37 cm L x 37 cm W x 37 cm H) with white interior was used for both 
the open field and the novel object recognition tasks. Objects for the novel object recognition task 
include a yellow semicircle (7.5 cm D x 3.5 cm H), green rectangular pyramid (7.5 cm L x 7.5 cm 
W x 7.5 cm H), red pyramid (8 cm L x 7 cm W x 6 cm H), and blue semi cylinder (7.5 cm L x 7.5 
cm W x 3.3 cm H). Noldus EthoVision XT (Version 11.5) measured the velocity, time spent in the 
perimeter (10 centimeters from the wall), and amount time investigating objects (calculated when 
the animal’s nose is four centimeters from the object).     
Fear Conditioning Chambers 
 For training and contextual day, two Freeze Monitor chambers (San Diego Instruments) 
measuring 25.4 cm (L) x 25.4 cm (W) x 19.05 cm (H) with stainless steel grid floors and Plexiglas 
walls was used. At the end of each session, chambers were cleaned with 50% Formula 409® 
(Chlorox). For cued fear, two chambers measuring 43.18 cm (L) x 12.7 cm (W) x 26.67 cm (H) 
with opaque walls and an added scent of vanilla was used to ensure a different visual and olfactory 
context. After each session, a solution of 10% ethanol was used to clean the chambers. To operate 
the chambers, they were connected to a computer running Freeze Monitor software (San Diego 
Instruments) and freezing behavior were recorded using Noldus EthoVision XT (Version 11.5) 
automated software.   
Tail Flick 
 Water in a 100 mL beaker was heated and maintained at 48 degrees Celsius on a heat plate. 
A Sony Handycam was used to record behavior during the task and independent observers blind 
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to treatment groups measured the amount of time it took for the animal to flick the distal ¼ portion 
of their tail out of the hot water bath.     
Drug Administration 
Induction of Diabetes  
Freshly prepared STZ was administered via intraperitoneal injection at a volume of 0.1 
mL/10 g to achieve a concentration of 40 mg/kg. Control mice were administered vehicle (citrate 
buffer) via intraperitoneal injection at a volume of 0.1 mL/10 g. Continual monitoring of blood 
glucose levels during STZ injections determined the timing and number of administrations, along 
with data from previous work in our laboratory (Murtishaw et al., in review). Animals were 
injected on days 1, 2, 3, 14, 15, 35, and 44 (the first day of STZ injections is Day 1). After STZ or 
citrate buffer vehicle administration, all animals were given 10% Ensure® (Abbott Laboratories) 
mixed in their water for 24 hours to counteract initial hypoglycemia due to insulin release from 
destroyed pancreatic beta cells (Szkudelski, 2001).  
During the experiment, blood glucose levels were monitored to confirm that the animals 
reached an elevated and sustained diabetic state. To measure blood glucose levels, lateral tail vein 
blood was collected after two hours of fasting. While gently restraining the animal, the withdrawal 
site was cleaned with alcohol. Using a sterile scalpel blade, lateral tail vein was nicked to obtain a 
small droplet of blood. AlphaTrak® Blood Glucose Monitoring System measured blood glucose 
levels. After the blood sample is obtained, gentle pressure was applied to the tail to stop the 
bleeding. Baseline measurements were collected a week before STZ injections. Measurements of 
blood glucose and weights were taken twice a week after injections begin. A reading of 250 mg/dL 
is considered hyperglycemic and equivalent to a diabetic state in mice (Atkinson, 2011). Baclofen 
treatments began when the STZ average blood glucose levels reached 250 mg/dL.   
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Baclofen treatment 
Mice received either baclofen (0.2 mg/mL) or saline vehicle at an injection volume of 0.1 
mL/g (intraperitoneal) to achieve a final concentration of 2 mg/kg. Injections were given twice 
daily (10 hours apart) for two weeks to maintain consistent activation of GABAB receptors 
throughout treatment. During the baclofen treatment, blood glucose was monitored twice a week.  
Behavioral Testing 
All behavioral tests were performed in a testing room separate from the colony room. 
Unless otherwise noted, behavior was tracked using an automated tracking system (Noldus 
EthoVision, Version 11.5). Behavioral testing began 36-hours after final baclofen injection to 
ensure complete metabolism of the drug.  
Open Field Task 
To assess anxiety phenotypes, behavior in the open field task was examined. Animals were 
be taken from the colony room and individually placed in the open field chambers located in a 
separate testing room. They were allowed to explore the chambers for five minutes while their 
activity (velocity, time spent in walls, and time spent in center) was recorded via the tracking 
system. At the end of the trial, animals were removed from the chambers and placed back in their 
home cage in the colony room. Chambers were cleaned with 10% ethanol solution before the next 
session.  
Novel Object Recognition (NOR) 
NOR is a widely used model to investigate memory alterations using a rodent’s innate 
exploratory behavior (Antunes and Biala, 2011). Twenty-four hours following the open field task, 
novel object recognition was performed. On Day 1, a pair of identical objects (either yellow 
semicircles, green rectangular pyramids, red pyramids, or blue semi cylinders were used and 
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counterbalanced across subjects) were placed in two corners of each chamber. Animals were given 
five minutes to explore the chamber and objects while the tracking system recorded the amount of 
time spent with each object. On Day 2 (twenty-four hours later), one of the objects from Day 1 
was replaced with a new object (novel object). During the five-minute trial, the tracking system 
measured the amount of time spent with the familiar and the novel object. Animals were removed 
at the end of the session and placed back in their home cage. Chambers were cleaned with 10% 
ethanol solution after each trial on each day.    
Cued and Contextual Fear Conditioning 
 To assess associative learning abilities, animals were trained and tested in a fear 
conditioning task. Twenty-four hours following Day 2 of novel object recognition, trace fear 
conditioning training began. Animals were individually placed in a testing chamber attached to the 
Freeze Monitor system. After two minutes of acclimatization in the testing chamber, a 2.9 kHz 88 
dB tone conditioned stimulus (CS) was presented for 30 second. At the cessation of the tone, a 4 
second delay occurred before the administration of a 1 second 0.3 mA foot shock (unconditioned 
stimulus; US). A total of four CS-US pairings was presented and separated by a two-minute 
interval. Freezing behavior was monitored during the first and last two minutes of the trial using 
the automated tracking system. After the session, animals were taken back to their home cage and 
the chamber was cleaned with 50% Formula 409® (Chlorox) solution.  
 Cued fear conditioning took place in an altered context chamber twenty-four hours after 
training. Animals were individually placed in a chamber and freezing behavior was continuously 
monitor by the automated tracking system. After two minutes in the chamber, the original CS tone 
was presented for 30 s every two minutes for a total of four presentations. At the end of the trial, 
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animals were taken back to their home cage and the chambers cleaned with 10% ethanol solution 
to ensure a different olfactory cue than on training day.  
 Contextual fear took place in the original training chamber twenty-four hours following 
cued fear. Animals were individually placed in the chambers and allowed to explore for ten 
minutes without any CS or US presentations. Freezing behavior was continually monitored by the 
automated tracking system and data binned into two minute intervals. Following the session, 
animals were placed back in their home cage and the chamber was cleaned with 50% Formula 
409® (Chlorox) solution.  
Tail Flick 
 To assess differences in nociception, the tail flick procedure was performed twenty-four 
hours after the last day of fear conditioning. Animals were taken into a separate room with a beaker 
of hot water (48 degrees Celsius). The last one-fourth portion of each animal’s tail was placed in 
the hot water bath and the latency with which the animal flicks its tail out of the hot water was 
recorded.  
 
Figure 1 Timeline of Experiment 
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Tissue Examination 
Tissue collection 
Animals were randomized within treatment groups for RT-PCR, western blotting, and 
immunohistochemistry tissue processing prior to tissue collection (n = 4 per procedure per 
treatment group). All animals will be humanely euthanized with carbon dioxide asphyxiation prior 
to transcardial perfusion of ice cold physiological saline. For RT-PCR and western blotting, brains 
were rapidly removed, the hippocampus and cortex dissected out, and flash frozen with liquid 
nitrogen before being stored in -80 degrees Celsius. For immunohistochemistry, 4% 
paraformaldehyde (PFA) solution was perfused following ice cold saline, whole brains were 
removed, and placed in to a vial of additional 4% PFA.  
SDS-PAGE Western Blotting 
 To examine protein expression of various targets outlined in Table 1, sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) Western blotting procedure was 
performed. Hippocampal and cortex tissue was homogenized using Bio-Plex® Cell Lysis Kit (Bio-
Rad), POLYTRON® homogenizer (Kinematica), a 24-hour -80-degree Celsius freeze/thaw, and 
sonication (Sonifer SFX150, VWR). Following sonication, samples were centrifuged at 4500 x g 
for 15 minutes and supernatant removed. Protein concentration was determined using Pierce® 
BCA Protein Assay Kit (Thermo Fisher Scientific). Samples (20 µg) were separated on 10% SDS-
PAGE gels and electro-transferred onto PVDF membranes (Immunobilon-FL, 0.45 micron; 
Millipore). Following blocking with Odyssey Blocking Buffer (LI-COR), membranes were probed 
with primary antibodies (see Table 1).  
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  After overnight incubation of primary antibodies on a shaker in 4 degree Celsius and 
subsequent washes, membranes were probed with fluorescence-based secondary antibodies (LI-
COR). After incubation and washes, membranes were imaged and analyzed using Odyssey® 
Infrared Imaging System (LI-COR) running Image Studio Software® (LI-COR). All proteins of 
interest were normalized to b-actin with the exception of the phosphorylated proteins (pTau and 
pGSK3b) which was normalized to the total protein (Tau and GSK3b, respectively).  
Table 1 SDS-Page Western Blotting Antibodies 
Antibody Description 
b-actin (1:20000; ProteinTech) Control antibody probed on the same 
membrane has proteins of interest as a loading 
control and will be used to normalize due to 
its stability across treatment manipulations.  
IDE (Insulin degrading enzyme; 1:1000; 
Abcam) 
 
Degrades Ab and insulin.  
GABABR1 (1:1000; Cell Signaling 
Technology) 
Obligatory GABAB receptor subunit that 
binds ligands. Antibody detects both pre- and 
post-synaptic isoforms of the receptor (1a and 
1b).  
GABABR2 (1:750; Cell Signaling 
Technology)  
Obligatory GABAB receptor subunit coupled 
to G proteins.   
GSK3b (1:1000; Cell Signaling Technology)  Kinase involved in phosphorylating tau.  
Phosphorylated GSK3b (1:1000; Cell 
Signaling Technology)  
Inactive form of GSK3b.  
Ab oligomers (1:1000; Abcam) Detects total oligomeric species of Ab. 
Tau (1:1000; Abcam) Detects total tau protein levels. 
Phosphorylated Tau (Serine 396; 1:1000; 
Santa Cruz Biotech) 
Detects levels of tau phosphorylated at serine 
396 and will be compared against total tau 
levels (pTau/Tau).  
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Immunohistochemistry 
Cortex and hippocampal coronal sections (15 µm thick) was sectioned on a cryostat 
(Hacker-Bright OTF5000) and stored free floating in 1xPBS at 4 degrees Celsius in plastic 12-
well plates.  
For staining to examine activated microglia, a procedure using the Iba1 antibody and 3,3’-
Diaminobenzidine tetrahydrochloride counterstain was used. Sections were blocked in 5% normal 
goat serum for 45 minutes then incubated overnight at 4 degrees Celsius in Iba1 antibody (Wako). 
The following day, sections were washed in 1xPBS (5 x 5 minutes) and incubated for 30 minutes 
with diluted biotinylated secondary antibody (ABC Kit; Vector Labs). After another 5 x 5 minute 
washes in 1xPBS, sections were incubated for 30 minutes with VECTASTAIN® ABC Reagent 
(ABC Kit; Vector Labs). Following a set of 5 x 5 minute washes, sections were stained with DAB 
(Sigma-Aldrich) diluted in 1xPBS and 0.03% hydrogen peroxide until color develops. Sections 
were immediately be washed in 1xPBS, mounted on slides, and cover-slipped.  
To examine microhemorrhages, the Prussian blue staining procedure was followed. 
Sections from the hippocampus and cortex were slide mounted and air dried overnight. The 
following day, sections were briefly rehydrated in water for 30 seconds, followed by incubation in 
freshly prepared 5% potassium ferrocyanide (Sigma Aldrich) and 5% hydrochloride acid (Sigma 
Aldrich) for 30 minutes. Following 5 x 5 minute washes in water, sections were counter stained in 
filtered 1% nuclear fast red solution for 5 minutes. Following 3 x 1 minute washes in water, 
sections were quickly dehydrated in succession of two dips in 95% ethanol, 100% ethanol, then 
xylene. Sections were then immediately covered-slipped. 
Images at 20x objective were taken of the cortex and hippocampus using a Zeiss Axioskop 
II Plus microscope (Carl Zeiss MicroImaging, Inc.). Two independent experimenters blind to the 
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treatment groups counted the cells expressing the Iba1 from the DAB counterstain and, separately, 
the microhemorrhages from the Prussian blue staining were counted.  
RT-PCR 
 To examine messenger RNA (mRNA) expression of pro- and anti-inflammatory cytokines 
associated with neuroinflammation (see Table 2) in hippocampal and cortex tissue, reverse 
transcriptase polymerase chain reaction (RT-PCR) was performed. mRNA was extracted from 
hippocampal and cortex tissue using RNeasy Mini Kit (Qiagen). mRNA concentration and quality 
was determined using a full spectrum spectrophotometer (NanoDrop 1000). Equal concentrations 
of mRNA per sample were reverse transcribed using QuantiNova Reverse Transcription Kit 
(Qiagen) in triplicates on Bio-Rad® C1000 Touch Thermal Cycler. Each sample of cDNA 
triplicate were run in triplicate with SsoAdvanced Universal SYBR Green Supermix (Bio-Rad) 
using Bio-Rad® CFX96 Real-Time PCR Detection System. The thermal cycling protocol was 
followed according to the recommended master mix instructions and as follows: 30 seconds at 95 
degrees Celsius (polymerase activation and DNA denaturation) then amplification consisting of 
15 seconds at 95 degrees Celsius (denaturation) and 30 seconds at 60 degrees Celsius 
(annealing/extension with plate read) for 40 cycles. Melt-curve analysis were performed following 
amplification at 65-95 degrees Celsius with a 0.5 degree increment every 5 seconds.  
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Table 2 RT-PCR Primer Targets 
Target Accession Number Description 
b-actin NM_007393.5 Control/normalizing housekeeping gene 
(Stephens et al., 2011).  
GAPDH (glyceraldehyde 3-
phosphate dehydrogenase) 
NM_008084.3 Control/normalizing housekeeping gene 
(Stephens et al., 2011). 
HPRT1 (hypoxanthine 
guanine phosphoribosyl 
transferase 1) 
NM_013556.2 Control/normalizing housekeeping gene 
(Stephens et al., 2011). 
TNF a (tumor necrosis 
factor alpha) 
NM_013693.3 Pro-inflammatory cytokine released by 
microglia and suggested to be elevated 
in AD (Bhaskar et al., 2014). 
IL-6 NM_031168.2 Pro-inflammatory cytokine released by 
glial cells and elevated in AD (Hüll et 
al., 1996). 
IL-1b NM_001513.1 Pro-inflammatory cytokine released by 
glial cells, elevated in AD, and 
implicated in vascular dementia (V 
Sharma, 2011). 
IL-1a NM_010554.4 Pro-inflammatory cytokine released by 
glial cells and elevated in AD (Rainero 
et al., 2004). 
IL-10 NM_010548.2 Anti-inflammatory cytokine released by 
glial cells. Reduction in IL-10 attenuates 
AD pathology (Guillot-Sestier et al., 
2015) 
 
Statistical Analyses  
Differences in blood glucose and body weights were analyzed by one-way between 
subjects analysis of variance (ANOVA) with group as the factor.  
Open field data using time spent (in seconds) in the border was analyzed by one-way 
between subjects ANOVA with group as the factor.  
Time spent investigating objects in Day 1 NOR was analyzed by one-way between subjects 
ANOVA with group as the factor. Time spent investigating the novel object over total time spent 
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investigating both novel and familiar objects in Day 2 NOR was compared using a Student’s t-test 
against chance (50%) for each treatment and control group.  
Time spent freezing in each day of CCF was analyzed by one-way between subjects 
ANOVA with group as the factor. Specifically, on CCF Training Day, only the first 120 seconds 
and the last 120 seconds was analyzed. Further, a Student’s t-test for each treatment and control 
group was performed comparing freezing during the first 120 seconds versus the last 120 seconds. 
On CCF Cued Day, the trial was divided into the following portions to analyze differences in 
freezing across the session: first 120 seconds, during cue 1, post cue 1, during cue 2, post cue 2, 
during cue 3, post cue 3, during due 4, and last 120 seconds. Finally, on CCF Contextual Day, 
freezing during two minute bins was analyzed.  
Western blotting data was analyzed by initially normalizing the protein of interest band to 
the control band (b-actin) or the phosphorylated form of the protein to the total protein (pTau/Tau 
or pGSK3b/GSK3b). Following normalization, proportion to control was determined by averaging 
all of the normalized control samples per membrane and setting the treatment subjects values over 
the averaged control values. Finally, the proportion to control for each sample was analyzed by 
one-way between subjects ANOVA with group as the factor.  
Immunohistochemistry cell counts were analyzed by one-way between subjects ANOVA 
with group as the factor.  
RT-PCR data were analyzed using threshold cycle value (Ct) normalized to housekeeping 
genes. Differences in the change of Ct (DCt) for experimental groups and control conditions were 
examined. DCt were analyzed by one-way between subjects ANOVA with group as the factor.  
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Tukey post-hoc comparisons of treatment groups was performed following any significant 
ANOVA to determine group significance.  
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CHAPTER 4 
RESULTS 
Induction of Diabetes 
Blood Glucose Levels 
 Confirmation of a diabetic state was made measuring blood glucose levels before STZ 
administration and twice a week after the first injection. The initial injection schedule was based 
on data from our laboratory (40 mg/kg STZ on day 1, 2, 3, 14, and 15; Murtishaw et al., in review) 
and additional two injections were required to achieve a group average of 250 mg/dL (Figure 2). 
Before the start of the STZ injections, the four groups had equivalent blood glucose measurements 
(F(3,44) = 0.8587, p = 0.4696). Significant increase blood glucose levels for both groups receiving 
STZ compared to controls began on Post Injection Day 17 (F(3,44) = 13.612, p = 0.000; Tukey post-
hoc analysis: Control versus STZ, p = 0.000; Control versus STZ Bac, p = 0.001). Both the STZ 
and STZ Bac group had significantly increased blood glucose levels across days before the 
beginning of the baclofen injections (Post Injection Day 6 through Post Injection Day 48; F(3,44) = 
43.386, p = 0.000; Tukey post-hoc analysis: Control versus STZ, p = 0.000; Control versus STZ 
Bac, p = 0.000). The baclofen injections resulted in a significant decrease in blood glucose levels 
in the STZ versus STZ Bac group (F(3,44) = 118.283; STZ versus STZ Bac, p = 0.000). However, 
the both the STZ and STZ Bac groups were significantly elevated compared to controls (F(3,44) = 
118.283, p = 0.000; Tukey post-hoc analysis: Control versus STZ, p = 0.000; Control versus STZ 
Bac, p = 0.000). Notably, no differences were observed between the controls and baclofen alone 
group (Controls versus Bac, p = 0.952). After the baclofen injections, blood glucose levels for both 
STZ administered groups remained elevated compared to saline (F(3,44) = 94.495, p = 0.000; Tukey 
post-hoc analysis: Control versus STZ, p = 0.000; Control versus STZ Bac, p = 0.000). Although 
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significantly elevated compared to saline, the STZ Bac group was significantly decreased 
compared to the STZ alone group (Tukey post-hoc analysis: p = 0.019). In short, STZ 
administration led to significantly elevated blood glucose measurements across days. Baclofen 
was able to decrease measurements in the STZ animals, suggesting its actions enhancing 
pancreatic beta cell function. However, the group averages for STZ Bac were still elevated 
compared to controls and baclofen alone.  
 
Figure 2 Blood Glucose Measurements. Mean blood glucose levels (± SEM) were 
significantly increased due to STZ administration. * = significantly different compared to 
controls (p < 0.05). # = significantly different compared to STZ Bac (p < 0.05).  
 
 
Body Weight  
 Body weights were recorded throughout the experiment to observe changes due to drug 
treatment. No differences were seen between groups with mean baseline body weight before 
injections began (Figure 3; F(3,44) = 0.302, p = 0.824). Similarly, no effect of treatment on body 
weights were observed during the STZ administration (F(3,44) = 0.281, p = 0.839), during baclofen 
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injections (F(3,44) = 0.533, p = 0.662) , or at the completion of the experiment (F(3,44) = 0.524, p = 
0.668). Therefore, the drug treatments in this experiment did not influence body weight.      
 
Figure 3 Body Weight Measurements. No significant differences in body weights (± SEM) 
were observed across the experiment.  
 
 
Behavioral Testing  
Open Field 
 The open field test was performed to assess anxiety phenotypes or locomotor changes that 
may manifest due to treatment. Time spent in the perimeter of the chamber was measured as well 
as velocity and distance travelled during the five-minute session. Although the averages for 
velocity (Figure 4B; F(3,44) = 0.483, p = 0.696) and total distance travelled (Figure 4C; F(3,44) = 
0.482, p = 0.697) are not statistically significant between treatment groups compared to controls , 
the STZ group displayed a trend towards significant increase in time spent in the perimeter of the 
chamber (Figure 4A; F(3,44) = 2.716, p = 0.056).  
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Figure 4 Open Field Data. No significant differences were observed for mean time spent (± 
SEM) in the perimeter of the chamber (A), velocity measured during the trial (B), or distance 
travelled (C). 
 
 
Novel Object Recognition 
 To evaluate learning and memory differences between treatment groups, the NOR test was 
performed. This task utilizes the rodents’ innate preference for novelty to measure memory 
abilities. On Day 1 of NOR, groups spent equivalent percent time with both of the identical objects 
(Figure 5A; F(3,44) = 1.094, p = 0.362) and displayed no differences in velocity (Figure 5B; F(3,44) 
= 0.805, p = 0.498) and distance travelled (Figure 5C; F(3,44) = 0.805, p = 0.498).  
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Figure 5 Day 1 Novel Object Recognition Data. A No differences were observed in percent 
time exploring both objects (± SEM). Mean velocity (± SEM; B) and distance travelled (± SEM; 
C) were equivalent between groups.  
 
 
On the following day, the novel object was introduced. Control and baclofen-treated (Bac) 
animals spent more time with the novel object, as revealed by a significant discrimination index 
for each group (Figure 6A; Control: t(11) = 2.572, p = 0.026; Bac: t(11) = 4.551, p = 0.001). The STZ 
group spent equal time with both objects (t(11) = 0.345, p = 0.737), indicating a lack of object 
recognition. Treatment with baclofen reversed this deficit, similar to what was observed in the 
control group and baclofen alone (STZ Bac: t(11) = 2.529, p = 0.028). No differences observed in 
velocity (Figure 6B; F(3,44) = 0.598, p = 0.62) and distance travelled (Figure 6C; F(3,44) = 0.568, p 
= 0.639). Therefore, insulin dysregulation induced by STZ administrations led to memory 
impairments that was attenuated by baclofen treatments.   
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Figure 6 Day 2 Novel Object Recognition Data. A Control, Bac, and STZ Bac spent 
equivalently more time with the novel object than the familiar object. The STZ group spent equal 
time with the novel and familiar objects. No differences were found with average velocity (± SEM; 
B) and distance travelled (± SEM; C). # = significantly greater than chance levels (p < 0.05). 
 
 
Cued and Contextual Fear Conditioning  
 Associative fear learning was assessed in the CCF task. During training on Day 1, freezing 
behavior was measured during the first 120 seconds (before the four CS-US pairings; Pre CS-US) 
and the last 120 seconds (after the four CS-US pairings; Post CS-US). No differences in freezing 
was observed between the treatment groups (Figure 7; Pre CS-US: F(3,44) = 1.233, p = 0.309; Post 
CS-US: F(3,44) = 0.447, p = 0.72). The amount of freezing significantly increased from Pre CS-US 
to Post CS-US within each treatment group (Figure 7; Control: t(11) = 14.895, p = 0.000; Bac: t(11) 
= 9.603, p = 0.000; STZ: t(11) = 11.27, p = 0.000; STZ Bac: t(11) = 15.722, p = 0.000), indicating 
that the CS-US pairings elicited fear behavior equally between all groups.  
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Figure 7 CCF Training Data. Mean percent freezing (± SEM) during the first 120 seconds 
before the CS-US pairings (Pre CS-US) and the last 120 seconds following the four CS-US 
pairings (Post CS-US). No differences were found between groups for both portions of the trial. 
Significantly increased freezing within all groups was observed comparing the Pre CS-US with 
Post CS-US (p < 0.05).  
 
 
 To examine if a learned association to the cue was made, the cue was presented in the 
altered context (Cued Fear) the following day. Freezing was measured before the presentation of 
the cue (Pre CS), during the condition stimuli (CS 1, CS 2, CS 3, and CS 4), and after the 
presentations of the cues (Post CS). No differences in freezing was observed during the first 120 
seconds before the presentation of the first cue (Figure 8; F(3,44) = 0.965, p = 0.418), indicating a 
lack of fear response to the altered context. Across the entire session, the STZ group displayed a 
significant increase in freezing during the cues compared controls (Figure 8; repeated measures 
ANOVA across cues, F(1,22) = 4.87, p = 0.038). Specifically, post-hoc analysis revealed that STZ 
displayed significant freezing during CS 2 (F(3,44) = 4.405, p = 0.009; Tukey post-hoc analysis: 
Control versus STZ, p = 0.009).  
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Figure 8 CCF Cued Fear Data. Mean percent freezing (± SEM) in the Cued Fear portion of 
CCF. A. Freezing before, during, and after cue presentations (CS 1, CS 2, CS 3, and CS 4). No 
differences in freezing before the presentations of cues. STZ displayed elevated freezing during 
the cues using repeated measures analysis (B.). * = significantly different (p < 0.05) compared to 
controls. 
 
 
 To test for a learned contextual fear association, the animals were placed back into the 
original training chamber and freezing behavior was measured. Across the ten minute session, no 
differences in freezing behavior was observed between groups (Figure 9; F(3,44) = 0.346, p = 0.792), 
suggesting a lack of difference in the learned association to the context. 
 
Figure 9 CCF Contextual Fear Data. Mean percent freezing (± SEM) in the original context 
in which the animals were shocked No differences in freezing between treatment groups was 
observed. 
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Tail Flick 
 The CCF task relies on equivalent nociceptive responses to acquire the learn association. 
Nociceptive differences were assessed using the tail flick task. All groups had equivalent latencies 
responded to the hot water bath (Figure 10; F(3,44) = 0.134, p = 0.939); therefore, pain threshold 
differences can be ruled out as a variable in CCF mean freezing levels. 
 
Figure 10 Tail Flick Data. No significant differences were observed between treatment groups 
in mean latency (± SEM) to remove the tail from a hot water bath.  
 
 
Tissue Examination 
SDS-Page Western Blotting 
 To examine protein changes due to effect of treatments, various AD pathology, insulin 
dysregulation, and GABAB receptor targets (Table 1) were examined.  
Protein levels of phosphorylated tau (pTau) was examined in the hippocampus and the 
cortex. A significant increase in pTau in proportion to total tau was observed in the hippocampus 
tissue of the STZ group (Figure 11A; F(3,26) = 7.329, p = 0.001; Tukey post-hoc analysis: Control 
versus STZ, p = 0.028) while no changes were observed for total tau in the hippocampus (F(3,28) = 
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0.332, p = 0.802). Cortex protein levels of pTau were unchanged between treatment groups (Figure 
11B; F(3,28) = 1.694, p = 0.191), consistent with the progression of AD pathologies.  
 
Figure 11 Western Blotting Data: Phosphorylated Tau/Tau. A. Representative images of the 
western blot for phosphorylated Tau/Tau (pTau/Tau) in the hippocampus. STZ group displayed a 
significant increase in protein levels compared to controls. B. Representative images of the western 
blots for pTau/Tau in the cortex. No significant differences were observed between treatment 
groups. * = significantly different from controls, p < 0.05. 
 
 
 To examine a major target in a potential mechanism of increased tau phosphorylation, 
GSK3b protein levels were analyzed in the hippocampus and the cortex. Phosphorylated GSK3b 
is the inactive form of the kinase and is inhibited from phosphorylating tau (Llorens-Martin et al., 
2014). In this analysis, the ratio of phosphorylated GSK3b (pGSK3b) to GSK3b were compared. 
In the hippocampus, no significant differences were observed between treatment groups (Figure 
12A; F(3,28) = 2.523, p = 0.078). However, the baclofen group displayed a trend in reduced 
pGSK3b/GSK3b (Tukey post hoc analysis: Control versus Bac, p = 0.076). No differences were 
seen in overall hippocampal GSK3b protein levels (F(3,28) = 0.614, p = 0.612). The cortex tissue 
did not reveal significant differences in pGSK3b between treatment groups (Figure 12B; F(3,28) = 
0.634, p = 0.599). Therefore, GSK3b levels were unchanged in this AD model. 
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Figure 12 Western Blotting Data: GSK3b. A. Representative images of the western blot in 
the hippocampus. No significant differences were observed in the mean proportion to control (± 
SEM) between treatment groups. B. Representative images of the western blot in the cortex. 
Similarly, no significant differences were found between treatment groups.  
 
 
In addition to pTau, another major pathology of AD are increased levels of total Ab 
oligomers. However, in this model, no changes in Ab oligomer levels with treatment of STZ in 
the hippocampus (Figure 13; F(3, 28) = 1.305, p = 0.292). Since no changes were found in the 
hippocampus, Ab oligomer levels in the cortex were not analyzed. 
 
Figure 13 Western Blotting Data: Ab Oligomers. Representative images of the western blot. 
No differences in protein levels for Ab Oligomers were found in the hippocampus.  
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Insulin degrading enzyme (IDE) protein levels were analyzed in the hippocampus and 
cortex to detect a mechanism of altered insulin dysregulation in AD. No changes were observed 
in either the hippocampus (Figure 14A; F(3,28) = 0.144, p = 0.933) or the cortex (Figure 14B; F(3,28) 
= 1.76), p = 0.178). Therefore, the mechanism of clearance of insulin and Ab in this model were 
unchanged. 
 
Figure 14 Western Blotting Data: IDE in Hippocampus and Cortex. A. Representative images 
of the western blot in the hippocampus. No significant differences were observed in the mean 
proportion to control (± SEM) between treatment groups. B. Representative images of the western 
blot in the cortex. Similarly, no significant differences were found between treatment groups.  
 
 
 GABAB receptor subunit protein levels were analyzed to see if the baclofen treatments 
resulted in receptor expression alterations. The obligatory GABABR2 protein levels were assessed 
in the hippocampus and cortex. However, no changes were found in either brain region 
(Hippocampus: Figure 15A; F(3,28) = 1.803, p = 0.170; Cortex: Figure 15B; F(3,28) = 0.009, p = 
0.999). Similarly, no differences were found in the two isoforms of GABAB1 receptor in the 
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hippocampus (Figure 15C; GABABR1a: F(3,28) = 1.442, p = 0.252; GABABR1b: F(3,28) = 0.112, p 
= 0.952). Baclofen administration did not alter overall GABAB receptor levels.  
 
Figure 15 Western Blotting Data: GABABR2 and GABABR1. A. Representative images of 
the GABABR2 western blot in the hippocampus. No significant differences were observed in the 
mean proportion to control (± SEM) between treatment groups. B. Representative images of the 
GABABR2 western blot in the cortex. Similarly, no significant differences were found between 
treatment groups. C. Representative images of the GABABR1 western blot in the hippocampus. 
No differences were observed between treatment group for either isoform of the receptor.  
 
 
Immunohistochemistry 
 Protein levels for phagocytic microglia (or reactive microglia) and histological staining for 
microvasculature hemorrhages were analyzed using immunohistochemistry.  
 Iba1 protein is specific for reactive microglia. In the hippocampus, a significant increase 
in the number of reactive microglia was observed for the STZ group (Figure 16A; F(3,183) = 3.998, 
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p = 0.009; Tukey post-hoc analysis: Control versus STZ, p = 0.005). In the cortex tissue, a 
significant increase was found between the STZ group receiving baclofen and the baclofen alone 
group (Figure 16B; F(3,187) = 3.168, p = 0.026; Tukey post-hoc analysis: Bac versus STZ Bac, p = 
0.05). The STZ group was not significantly different from controls in the cortex (Control versus 
STZ, p = 0.343). These results suggest that STZ administration leads to reactive microglia in the 
hippocampus and elevated, yet not significant numbers in the cortex. The combination of STZ and 
baclofen treatments leads to increase number of Iba1 positive microglia in the cortex compared to 
baclofen alone.  
 
Figure 16 Immunohistochemistry Data: Iba1. A. Representative images of Iba1 positive 
microglia in the hippocampus. The STZ group had significantly more Iba1 microglia versus 
controls. B. Representative images of Iba1 positive microglia in the cortex. The STZ Bac group 
displayed an increase number of Iba1 positive microglia compared to the Bac group. * = 
significantly different from control, p < 0.05. # = significantly different from Bac, p < 0.05. 
 
 
 Microvascular hemorrhages are found in AD and diabetic patients. As revealed by Prussian 
blue staining, the number of microvascular hemorrhages were not statistical significant between 
treatment groups in the hippocampus (Figure 17A; F(3,43) = 0.217, p = 0.189) and in the cortex 
(Figure 17B; F(3,44) = 1.034, p = 0.387). Based on these results, STZ treatment did not result in 
microhemorrhages during the time frame of this experiment.  
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Figure 17 Immunohistochemistry Data: Prussian blue. No changes were observed between 
treatment groups in the number of microhemorrhages in the hippocampus (A.) or the cortex (B.). 
 
 
RT-PCR 
 Cytokine mRNA levels associated with AD were measured using RT-PCR. IL-1b is a pro-
inflammatory cytokine that is increased in AD patients. In this experiment, IL-1b RNA expression 
was significantly increased in the STZ group in the hippocampus (Figure 18A; F(3,44) = 10.1928, p 
= 0.000; Tukey post-hoc analysis: Control versus STZ, p = 0.000). The STZ group displayed 
significantly reduced RNA expression in the cortex compared to the baclofen group, but not the 
control group (Figure 18B; F(3,44) = 5.834, p = 0.0019; Tukey post-hoc analysis: Control versus 
STZ, p = 0.1407; Bac versus STZ, p = 0.0009). These results demonstrate that STZ administration 
is able modulate pro-inflammatory cytokine levels in a region-specific manner. 
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Figure 18 RT-PCR Data: IL-1b. A. The STZ group displayed significantly increased levels 
of IL-1b RNA in the hippocampus compared to controls. B. The STZ group had significantly 
reduced IL-1b RNA compared to the baclofen alone group. * = statistically significant versus 
controls, p < 0.05. # = statistically significantly versus baclofen, p < 0.05.  
 
 
 IL-10 anti-inflammatory RNA levels were examined in the hippocampus and cortex. The 
STZ group displayed a significant increase in IL-10 RNA levels in the hippocampus (Figure 19A; 
F(3,44) = 11.8987, p = 0.000; Tukey post-hoc analysis: Control versus STZ, p = 0.000). In the cortex, 
the baclofen group displayed significantly elevated RNA levels compared to controls while no 
changes were found in the STZ group (Figure 19B; F(3,44) = 15.8617, p = 0.000; Tukey post-hoc 
analysis: Control versus Bac, p = 0.000).  
 
0
0.5
1
1.5
2
2.5
3
M
ea
n 
Pr
op
or
tio
n 
to
 C
on
tro
l
Hippocampus
IL-1β
Control
Bac
STZ
STZ Bac
*
A. B.
0
0.5
1
1.5
2
2.5
3
M
ea
n 
Pr
op
or
tio
n 
to
 C
on
tro
l
Cortex
IL-1β
Control
Bac
STZ
STZ Bac#
 
 
 
60 
 
Figure 19 RT-PCR Data: IL-10. A. The STZ group displayed significantly increased levels of 
IL-10 RNA in the hippocampus compared to controls. B. The baclofen group revealed significantly 
elevated IL-10 RNA expression compared to the controls. * = statistically significant versus 
controls, p < 0.05.  
 
 
 Other pro-inflammatory markers were assessed in the hippocampus. Both groups given 
STZ (STZ and STZ Bac) displayed a significant decrease in TNF a RNA levels (Figure 20A; F(3,44) 
= 9.3223, p = 0.0001; Tukey post-hoc analysis: Control versus STZ, p = 0.0003; Control versus 
STZ Bac, p = 0.0039). The baclofen group exhibited a significant increase with both IL-1a (Figure 
20B; F(3,44) = 3.0885, p = 0.0367; Tukey post-hoc analysis: Control versus Bac, p = 0.0362) and 
IL-6 (Figure 20C; F(3,44) = 3.3211, p = 0.0282; Control versus Bac, p = 0.0311) in the hippocampus. 
Both the STZ administration and, separately, the GABAB agonist influences pro-inflammatory 
markers.  
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Figure 20 RT-PCR Data: TNF a, IL-1a, and IL-6. A. The STZ and STZ Bac group displayed 
significantly lower RNA expression levels of TNF a in the hippocampus compared to controls. B. 
The baclofen group revealed significantly elevated IL-1a RNA expression compared to the 
controls in the hippocampus. C. The baclofen group show elevated IL-6 RNA levels in the 
hippocampus. * = statistically significant versus controls, p < 0.05.   
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CHAPTER 5 
DISCUSSION 
 The purpose of this study is to examine the role of GABAB receptors on neuroinflammation 
and AD pathology in a diabetes rodent model. We found that inducing hyperglycemia using the 
compound STZ resulted in behavioral, biochemical, and inflammatory changes similar to what is 
observed in other AD rodent models and in the AD patient population. Further, we found that 
administration of a GABAB receptor agonist (baclofen) attenuated the AD-related behavior deficits 
and pathologies induced by STZ.  
 Analysis of a diabetic-like state during STZ injections was made by measuring blood 
glucose levels. STZ is capable of producing mild to severe diabetes depending on dosage and 
schedule of administration (Deeds et al., 2011). A single, high doses of STZ (100-200 mg/kg IP) 
leads to a severe hyperglycemic state, with excessively high blood glucose levels (>400 mg/dL) 
occurring rapidly in animals and a 70±7% mortality rate (Lu et al., 1998; Ito et al., 1999; Hayashi 
et al., 2006; Bloch et al., 2006). The choice of a low-dose (40 mg/kg IP), staggered protocol used 
in this experiment reflects our concerns over the permanent destruction of pancreatic beta cells 
that would result in little to no production of insulin does not result in AD pathologies. STZ-
induced diabetes can be highly variable and a clear, standard protocol does not exist in the literature 
(Deeds et al., 2011). Variability in response to STZ occurs between mouse strains and also within 
subgroups (age, vendor, and even inbred strain) of the same genetic background, complicating the 
STZ administration protocol (Gurley et al., 2006; Deeds et al., 2011). A low-dose, staggered 
protocol allows researchers to monitor the level blood glucose to determine if another STZ 
administration is necessary throughout the experiment and to avoid irreversible and extensive 
toxicity. STZ has acute effects (24-48 hours) and longer term effects (up to two weeks) on 
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pancreatic beta cells (Deeds et al., 2011). Immediately after administration, the destruction of 
pancreatic beta cells results in excessive insulin release and hypoglycemia (Szkudelski, 2001). The 
drop in insulin production can be observed by the increase in blood glucose levels. Some of the 
surviving cells begin to die within two weeks after STZ due to infiltration of lymphocytes, further 
increasing blood glucose levels (Like and Rossini, 1976; OBrien et al., 1996). The pattern can be 
observed by a gradual increase of blood glucose levels over time that eventually plateaus (Figure 
2). In this experiment, our goal was to achieve a group average of 250 mg/dL to avoid mortality 
that can occur with significantly elevated hyperglycemia. After seven intermittent injections on 
days 1, 2, 3, 14, 15, 35, and 44, blood glucose levels reached an average of 250 mg/dL with zero 
mortality rate among our animals.  
 Administration of the GABAB receptor agonist, baclofen, had an interesting effect on blood 
glucose levels. Pancreatic beta cells produce and respond to the neurotransmitter GABA, where it 
plays a role in regulating insulin secretion (Wan et al., 2015). In addition to beta cells, the pancreas 
contains alpha cells that increases insulin secretion in response to GABA (Brice et al., 2002). 
Although the signaling mechanism of GABA on beta and alpha cells is not fully elucidated, a 
proposed mechanism exists. For example, it is thought that beta cells release insulin in response to 
increasing glucose levels, which activates insulin receptors on alpha cells. This leads to the 
translocation and subsequent upregulation of GABAA receptors on the alpha cell surface that 
increases membrane depolarization resulting in the inhibition of glucagon release (E Xu et al., 
2006). Glucagon is a hormone that has the opposite function of insulin in that can increase glucose 
levels in the blood. This pathway has suggested to be disrupted in diabetic patients that results in 
unsuppressed glucagon secretion (Wan et al., 2015).  
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Pancreatic beta cells respond differently compared to alpha cells in the presence of GABA, 
where GABA results in membrane depolarization and subsequent release of insulin (Dong et al., 
2006; Braun et al., 2010; Soltani et al., 2011). However, studies investigating GABAB receptor 
modulation on insulin release have shown conflicting results. For example, GABAB receptors 
suppress insulin release in the presence of high glucose concentrations (over 180 mg/dL) (Gu et 
al., 1993; Brice et al., 2002) but have no effect on lower glucose levels (Brice et al., 2002; Wan et 
al., 2015). In addition, pre-treating non-obese diabetic mice (transgenic mice that develop diabetes 
without the weight gain) with baclofen delays the onset of diabetes and increases beta cell 
proliferation (Beales et al., 1995). Conversely, mice lacking GABAB receptors (specifically, 
GABABR1 subunit) exhibit increased pancreatic insulin release compared to wildtype controls 
(Szkudelski, 2001). In our experiment, activation of pancreatic GABAB receptors via baclofen 
appeared to have a slightly beneficial effect. After two days of the baclofen treatment, the STZ 
Bac group displayed significantly decreased levels compared to the STZ group (see Figure 2). 
Importantly, the reported decrease in blood glucose levels was still significantly increased 
compared to the control and baclofen alone groups. Therefore, the STZ Bac displayed significantly 
elevated blood glucose levels despite the influence of pancreatic GABAB receptors. 
The memory impairments in NOR exhibited by the STZ group are consistent with those 
reported in AD patients and preclinical rodent models (Görtz et al., 2008; Ambrée et al., 2009). 
The NOR task relies on proper functioning of the hippocampus, in that hippocampal lesions result 
in impairments in discrimination between familiar and novel objects (Antunes and Biala, 2012). 
In AD, the entorhinal cortex and hippocampal formation are primarily affected in the initial stages 
of the disease (H Braak and E Braak, 1991; 1997). Insulin deficiency produces impairments in 
hippocampal synaptic plasticity and neurogenesis that underlie cognitive deficits (Stranahan et al., 
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2008; Murtishaw et al, in review; Prickaerts et al., 1999; Y Chen et al., 2013; Jabbarpour et al., 
2014). Treatment with baclofen for two weeks prior to testing was able to reverse the STZ-induced 
deficits. As no differences between baclofen alone and control group were found, this suggests 
that the action of baclofen may be mediated through the attenuation of STZ-induced 
neuroinflammation and phosphorylated tau also found in this study.  
Conditioned fear learning was assessed in this model using CCF. The neurological 
mechanisms of fear conditioning are well studied and highly conserved across species (LeDoux, 
1994). Our experiment used a variation in CCF training protocol called trace conditioning, where 
there is a time interval separating the offset of the tone and the onset of the shock. This protocol 
increases the level of difficulty in associating of the auditory cue and the contextual environment 
with the shock. Lesion studies demonstrate that the cued fear association portion of this task 
(responding to the cue alone in an altered context from which subjects were shocked) is dependent 
on both the hippocampus and amygdala, while the context portion of the task (responding the 
environment in which they were shocked without cue presentations) depends primarly on the 
hippocampus (Solomon and Vander Schaaf, 1986; Moyer et al., 1990; Sutherland and RJ 
McDonald, 1990; C Chen et al., 1996). In AD, amygdalar-hippocampal communication is 
disrupted, resulting in impaired acquired conditioned fear response (Hamann et al., 2002). 
Preclinical AD models also show fear response deficits in CCF (Webster et al., 2014) (Kilgore et 
al., 2010; Hanna et al., 2012). In our study, animals exhibited equal freezing behavior after the 
presentation of the conditioned stimulus (CS) and unconditioned stimulus (US) pairings during the 
training session. In the Cued Fear session, the STZ group displayed an increase in freezing 
behavior compared to controls across the presentation of the cues. This increase in freezing may 
reflect an anxiolytic phenotype. Similar to what was observed in the open field test, where the data 
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hint at anxiety-like behavior with the STZ group, in that these animals had a nonsignificant trend 
towards more time in the perimeter of the chamber. Studies have reported that metabolic disorders 
and STZ-induced diabetes can lead to increased reactivity of the HPA axis, which results in 
hypersensitivity and the inability to effectively shut off the stress response (Scribner et al., 1991; 
Magariños and McEwen, 2000; Ikeda et al., 2015). Changes in pain response were also evaluated 
using the tail flick test and no differences were observed. Interestingly, all groups showed 
equivalent freezing behavior in the Contextual Fear portion, the session that has the most 
hippocampal contribution. It is possible that cue and the context are too salient to detect a 
difference between groups, even with the more challenging trace conditioning training protocol.  
Several protein targets associated with AD were analyzed in the hippocampus and cortex 
of animals in this experiment to understand the molecular mechanisms linking diabetes and the 
effect of baclofen administration. No changes in Ab oligomers were observed between treatment 
groups. This is not surprising as the metabolism of APP in rodents is different compared to humans 
and they do not develop toxic Ab oligomers. Typically, transgenic animals expressing human APP 
or direct infusion of Ab42 peptides into the brain in non-transgenic rodent models display 
significant changes in brain Ab oligomers. Along with the lack of changes in Ab, no differences 
IDE protein levels were found between treatment groups. Even though STZ results in insulin 
dysfunction, IDE may not be affected without the competition of elevated Ab. However, region 
specific changes with phosphorylated tau were found in the STZ group. The STZ group had 
significantly increased phosphorylated tau in the hippocampus that was attenuated by the baclofen 
administration. Increased levels of phosphorylated tau correlate with cognitive and memory 
deficits, similar to what was observed in NOR with the STZ group. The lack of change with 
phosphorylated tau in the cortex is consistent with Braak staging in AD, with NFT beginning in 
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the hippocampus initially then eventually appearing in the cortex in late stages of the disorder (H 
Braak and E Braak, 1991; 1997; H Braak et al., 2006). As mentioned previously, NFTs (composed 
of hyperphosphorylated tau) have high correlation with poor memory performance in AD patients 
and in preclinical models (H Braak and E Braak, 1991; Arriagada et al., 1992; Bancher et al., 1993; 
H Braak and E Braak, 1997; Guillozet et al., 2003; SantaCruz, 2005). For example, in a study 
using a preclinical AD model with tau mutations, untreated transgenic mice displayed significant 
deficits in the NOR task while administration of a phosphorylated tau antibody ameliorated the 
impairment (Sankaranarayanan et al., 2015). To examine a potential mechanism of increased 
phosphorylated tau associated with AD, we analyzed GSKb levels in the hippocampus and cortex. 
Over-activity of GSKb can lead to increases in phosphorylated tau, memory impairments, and Ab 
oligomer production (Hooper et al., 2007). However, no changes were observed in GSKb protein 
levels in hippocampus or cortex between treatment groups. According to several AD hypotheses, 
Ab peptides indirectly leads GSK3b activity which then all contribute to phosphorylated tau 
(Terwel et al., 2008; Dewachter et al., 2009; Kremer et al., 2011). Therefore, hyperphosphorylated 
tau may have occurred through increased inflammation in this study rather than through altered 
GSK3b signaling that was attenuated by reduced inflammation via GABAB receptor activation. 
 Neuroinflammation and neuroinflammatory markers were examined in this experiment, as 
they are a characteristic of diabetes and AD pathology (Mrak and Griffin, 2005a). Microglia 
constantly survey the environment and receive signals from surrounding cells. Brain tissue injury, 
invading pathogens, and pathological conditions associated with neurological disorders can cause 
microglia to be reactive, a state in which they surround and attempt to clear the debris. In addition, 
microglia change their morphology, upregulate cell-surface receptors, and release cytokines, 
chemokines, and other factors with the goal of repairing and restoring the area to homeostasis 
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(Solito and Sastre, 2012). While this response proves to have immediate beneficial effects in the 
brain, sustained neuroinflammation due to pathological conditions, such as those seen in AD, can 
lead to damage and accumulation of the pathogen that initially triggered the response. Our 
hypothesis was that administration of STZ would lead to an increased number of reactive 
microglia, elevated pro-inflammatory cytokines and an increase in anti-inflammatory cytokines, 
as neuroinflammation has been demonstrated to produce cognitive deficits in similar studies using 
STZ (Biessels et al., 1998; 2007; Jabbarpour et al., 2014). 
Our results showed that the STZ group displayed an increased number of reactive microglia 
and elevated IL-1b pro-inflammatory cytokine RNA levels in the hippocampus but not the cortex. 
Microglia and IL-1b can influence the phosphorylation of tau. Consistent with data from our study, 
elevated expression IL-1b leads to increased phosphorylated tau (Yuekui Li et al., 2003; Gorlovoy 
et al., 2009) and overexpression of IL-1b in the hippocampus of non-APP mice lead to memory 
impairments (Moore et al., 2009; Hein et al., 2010; DC Lee et al., 2013). Treatment with baclofen 
reduced the number of reactive microglia, expression of IL-1b, and phosphorylated tau induced 
by STZ back to control and baclofen alone levels in the hippocampus. Therefore, it appears that 
the reactive microglia and the pro-inflammatory cytokine IL-1b in the STZ be involved in the 
hyperphosphorylated tau and behavioral deficits that are all reversed by GABAB activation.  
Our results also found increased expression of IL-10 RNA in the hippocampus of the STZ 
group, while the baclofen alone group had significant elevated RNA expression of IL-10 in the 
cortex. IL-10 is an anti-inflammatory cytokine and is a key player in controlling the immune 
response in the brain (Wyss-Coray and Mucke, 2002; Williams et al., 2004; Ming O Li and Flavell, 
2008). Studies have reported increased levels of IL-10 protein and RNA in preclinical models of 
AD (Apelt and Schliebs, 2001; Heneka and OBanion, 2007) while no correlation in AD patient 
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tissue has been found (Apelt and Schliebs, 2001). Increases in anti-inflammatory markers may be 
attempting to counteract actions of reactive microglia and pro-inflammatory cytokines. The STZ 
group showed a region-specific elevation with IL-10 that correlates with the region-specific 
changes in reactive microglia, phosphorylated tau, and IL-1b data that is also reversed by the 
administration of baclofen. Conversely, the region-specific changes with the baclofen alone group 
is puzzling. However, one should keep in mind that neuroinflammatory processes are highly 
interactive and do not occur in isolation. Amplification of one mediator leads to a dampening of 
another which all interact and influence different inflammatory pathways. Therefore, elevation of 
IL-10 RNA in the cortex requires further elucidation.   
TNFa is another common pro-inflammatory cytokine associated with AD and diabetes 
examined in this study. We found a significant decrease in TNFa RNA expression levels in both 
the STZ and STZ Bac group in the hippocampus. In AD patients and preclinical models, as well 
as diabetic patients and STZ preclinical models, TNFa is significantly elevated (Dickson et al., 
1993; Benzing et al., 1999; Limb et al., 1999; Mehlhorn et al., 2000; Carmo et al., 2000; Krady et 
al., 2005; Gezen-Ak et al., 2013), where it is found to be a mediator of acute and chronic 
inflammation and activated by Ab-induced cytotoxicity in AD (PB Rosenberg, 2005). However, 
researchers have suggested that TNFa levels may wax and wane during different stages of AD. 
For example, a study examining brain tissue of AD patients found lower TNFa levels in the cortex 
and hippocampus of AD patients compared to healthy age-matched controls (Lanzrein et al., 1998) 
that correlated with a previous study that found lower TNFa serum levels (Cacabelos et al., 1994). 
Low levels of TNFa in AD may be indicative of a dysfunctional inflammatory process (Lanzrein 
et al., 1998; Gezen-Ak et al., 2013). In addition, high levels of IL-10 can inhibit the synthesis of 
TNFa (PB Rosenberg, 2005), which correlates with our findings in the STZ group. Whether 
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elevated IL-10 RNA expression in the STZ group is inhibiting TNFa or if there is altered 
neuroflammatory processes induced by STZ is unclear in this experiment. However, the reduction 
in TNFa in the STZ group was not rescued by the baclofen treatment, suggesting that GABAB 
activation was not able to modulate this cytokine.  
IL-6 RNA levels were increased in the hippocampus of the baclofen alone group. IL-6 is 
detectable at low levels in healthy adults and significantly elevated under pathological conditions 
(Vallières and Rivest, 1997). Although IL-6 can add to detrimental AD pathology, it does exhibit 
immunosuppressive and anti-inflammatory properties under certain conditions. Several studies 
have found that IL-6 regulates neuronal survival and function (Gadient and Otten, 1997; Gruol and 
Nelson, 1997; Campbell, 1998; Feng et al., 2015). Specifically, one study found that baclofen 
attenuated lipopolysaccharide-induced increase in IL-6 in microglia cell culture. Further, the same 
study showed that baclofen alone dose-dependently reduced IL-6 released by microglia (Kuhn et 
al., 2004). Similarly, the baclofen alone group displayed increases in the pro-inflammatory IL-1a 
in the hippocampus. Although IL-b and IL-1a bind to the same receptor, little is discussed about 
the role of IL-1a in AD or diabetes. Therefore, the increases in IL-6 and IL-1a levels after GABAB 
receptor activation require further evaluation. 
Administration of baclofen attenuated the STZ-induced levels of several 
neuroinflammatory markers and memory deficits. Reactive microglia increase their expression of 
GABAB receptors (Kuhn et al., 2004), suggesting that they play a role in regulating 
neuroinflammation. Microglia GABAB receptors attenuate the release of lipopolysaccharide-
induced IL-6 but does not influence TNFa release (Kuhn et al., 2004). We examined GABAB 
receptor subunit protein expression in the hippocampus and cortex in the treatment groups. 
Although no differences were found, there appears to be a trend towards an increase in both of the 
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groups who received baclofen (Bac and STZ Bac) for the GABABR1a isoform in the hippocampus. 
However, the homogenized tissue examined was not specific to microglia and detects neuronal 
GABAB receptor levels as well. Alterations in neuronal GABAB receptor levels could disrupt the 
synchrony and network of systems within the brain and have deleterious implications on learning 
and memory (Heaney and Kinney, 2016). If the treatments in this experiment altered the levels of 
microglial GABAB receptors, using the western blot procedure would not be sensitive enough to 
detect changes. Given the data we have with baclofen administration in STZ animals (rescue in 
memory impairment, phosphorylated tau, reactive microglia number, IL-1b, and IL-10), we can 
indirectly infer that GABAB receptors play a role in modulating microglia function. 
Overall, this experiment demonstrates that administration of STZ leads to select AD 
pathologies and microglia-induced neuroinflammation that are ameliorated by chronic activation 
of GABAB receptors. Further studies are required to outline mechanism by which STZ leads to 
AD-related behavior and protein changes in the brain. For instance, examining insulin receptor 
number and resistance would be beneficial in stating how much insulin dysregulation contributes 
to the neuroinflammation with our STZ model. With regards to future studies using baclofen in a 
STZ model, intracerebroventricular infusions instead of systemic administration should be a 
consideration to bypass the effect baclofen had on pancreatic beta cells. Limitations to the present 
study include a direct link to GABAB specifically on microglia. Using flow cytometry that selects 
for specific proteins on microglia would be advantageous in providing a direct link to the current 
study. Further, evaluating the effects of STZ administration in a mouse model that lack GABAB 
receptors specifically on microglia can shed light on immune functions. By crossing CX3CR1 
mice (CX3CR1 are receptors expressed only by microglia in the brain (Cardona et al., 2006)) with 
Cre/Lox inducible GABABR1lox511/lox511 mice, we can induce the inactivation of GABAB receptors 
 
 
 
72 
on microglia. We could then evaluate behavior and biochemical changes after STZ administration 
in these animals to elucidate the role of GABAB receptors on microglia. Even though questions 
remain to be answered regarding how GABAB receptors are involved in the neuroinflammatory 
response, this study provides data that demonstrates GABAB receptor activation attenuates 
neuroinflammatory markers and subsequent AD pathologies.  
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Comparison of postnatal ketamine dosage on behavioral deficits in adulthood. 
Poster presented at The Sierra Nevada Chapter for Society for Neuroscience 4th 
Annual Research Symposium in Reno, NV 2012. 
Bolton MM, Heaney CF, Sabbagh JJ, Murtishaw AS, Magcalas CM, Kinney JW. 
Comparison of postnatal ketamine dosage on behavioral deficits in adulthood. 
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Poster presented at Society for Neuroscience annual meeting New Orleans, LA 
2012. 
Bolton MM, Heaney CF, Sabbagh JJ, Murtishaw AS, Kinney JW (2011, November).  
Comparison of an Adult and Developmental Animal Model of Schizophrenia. 
Poster  
presented at Society for Neuroscience annual meeting in Washington, D.C. 
 
Invited Speaking Engagements 
 
Association for Psychological Science Student Caucus Invited Panelist: May 2014. 
Invited to speak at a panel during the Association for Psychological Science (APS) 
national conference. The panel is organized by the APS Student Caucus and titled “The 
Naked Truth Part II: Surviving Graduate School.”  
Psi Chi International Honor Society in Psychology, UNLV Local Chapter, Invited 
Panelist: January 2015: Invited to speak on a panel during the Psi Chi UNLV Local 
Undergraduate Chapter meeting. The panel consisted of current graduate students 
discussing their experience getting into graduate school and life in graduate school.  
 
Awards/Grants: 
 
Doctoral Graduate Research Assistantship: Fall 2015 – Spring 2016 ($15,500).  
Examination of biomarkers and novel treatments in Alzheimer’s disease.  
 
Patricia Sastaunak Scholarship: Fall 2015 – Spring 2016 ($2,500). Competitive  
university-wide scholarship awarded to graduate students who have demonstrated 
substantial academic accomplishments.   
 
University of Nevada, Las Vegas Graduate Professional Student Association Travel 
Award: Summer 2015 ($450). University-wide travel grant to aid students with funding 
to present research at national conferences. This award was given to fund travel to the 
International Behavioral Neuroscience Society Annual Meeting in Victoria, B.C., 
Canada. 
 
Outstanding Presentation Award, University of Nevada, Las Vegas Graduate and  
Professional Student Association Annual Research Forum: Spring 2015.  
 
University of Nevada, Las Vegas Graduate Professional Student Association Travel 
Award: Fall 2014 ($800). University-wide travel grant to aid students with funding to 
present research at national conferences. This award was given to fund travel to the 
Society for Neuroscience conference in Washington, D.C. 
 
University of Nevada, Las Vegas Graduate Professional Student Association Travel 
Award: Summer 2014 ($200). University-wide travel grant to aid students with funding 
to present research at national conferences. This award was given to fund travel to the 
Association for Psychological Sciences conference in San Francisco, CA.  
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Outstanding Presentation Award, University of Nevada, Las Vegas Graduate and  
Professional Student Association Annual Research Forum: Spring 2014.  
 
Patricia Sastaunak Scholarship: Fall 2013 – Spring 2014 ($2,500). Competitive  
university-wide scholarship awarded to graduate students who have demonstrated  
substantial academic accomplishments. 
 
University of Nevada, Las Vegas Graduate Professional Student Association Travel 
Award: Fall 2013 ($400). University-wide travel grant to aid students with funding to 
present research at national conferences. This award was given to fund travel to the 
Society for Neuroscience conference in San Diego, CA.  
 
Patricia Sastaunak Scholarship: Fall 2012 – Spring 2013 ($2,500). Competitive  
university-wide scholarship awarded to graduate students who have demonstrated  
substantial academic accomplishments.   
 
University of Nevada, Las Vegas Graduate Professional Student Association Travel  
Award: Fall 2012 ($450). University-wide travel grant to aid students with funding to  
present research at national conferences. This award was given to fund travel to Society 
for Neuroscience conference in New Orleans, LA.  
 
Outstanding Presentation Award, University of Nevada, Las Vegas Graduate and  
Professional Student Association Annual Research Forum: Spring 2012.  
 
University of Nevada, Las Vegas Graduate Professional Student Association Travel 
Award: Fall 2011 ($350). University-wide travel grant to aid students with funding to  
present research at national conferences. This award was given to fund travel to the 
Society for Neuroscience conference in Washington, D.C. 
 
University Memberships: 
 
University of Nevada, Las Vegas Psychology Department Experimental Graduate 
Student Committee President: Fall 2012 – Spring 2013. Student-elected position to act 
as the liaison between the psychology department faculty and graduate students. 
Responsibilities include running committee meetings, attend faculty meetings, write 
faculty meeting minutes, and organize Interview Day activities for potential incoming 
graduate students.  
 
University of Nevada, Las Vegas Psychology Department Experimental Graduate 
Student Committee Secretary: Fall 2011 – Spring 2012. Student-elected position to 
document details of the committee meetings. Responsibilities include attending 
committee meetings and taking notes, writing and e-mailing meeting minutes to the 
department, communicate with other graduate students in the department regarding 
activities, and organizing the end of the year party and other  
events.  
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Graduate Neuroscience Association, Co-Founder and Committee Member: Fall 2011 
to present. An association intended to inform graduate students about current research in 
the field of neuroscience.  
 
Neuroscience Journal Club, Co-Founder and Secretary: Fall 2010 – present. An 
organization formed to educate undergraduate students about the field of neuroscience, 
how to read and analyze scientific articles, and organize events in the community.  
   
Professional Memberships: 
 
Medical Science Liaison Society member since 2016 
American Association of Pharmaceutical Sciences member since 2015 
National Association of Professional Women member since 2015 
International Behavioral Neuroscience Society member since 2013 
Association for Psychological Science member since 2013 
Society for Neuroscience, Sierra Nevada Chapter member since 2010 
 Society for Neuroscience member since 2009 
 
Service:  
International Behavioral Neuroscience Society, Student Councilor Elect 2017 
 
Communications and Media Committee Member for the International Behavioral 
Neuroscience Society: January 2015 to present. Recruit members from all over the world 
to join the organization, advertise the society on social media, maintain social media 
platforms, and interview professionals in the field of behavioral neuroscience to promote 
the organization.   
International Student Representative Nominee for the International Behavioral 
Neuroscience Society: June 2015. Nominated as a candidate to represent students 
(graduate and post-doctoral) from all over the world on the International Behavioral 
Neuroscience Society advisory council.   
Psi Chi International Honor Society in Psychology, UNLV Local Chapter Research 
Forum Judge: April 2015. Neuroscience judge for the university undergraduate Psi Chi 
chapter.  
UNLV College of Sciences Science Fair Judge: March 2015. Behavioral and Social 
Science judge for a regional high school science fair.  
Las Vegas Brain Bee Organizer and Judge: February 2015. Appointed as the Logistics 
Coordinator and one of three judges for the Las Vegas Brain Bee. Participants were local 
high school students demonstrating their knowledge in neuroscience. The winner from 
this competition was sent to the National Brain Bee. 
Brain Education Week, Head Coordinator for the Clark County School District: 
Fall 2014. Work with representatives from the Clark County School District to 
incorporate Brain Awareness presentations and knowledge regarding the brain and 
nervous system into school curriculum starting in the 2014-2015 school year.   
Brain Safety Initiative of the International Behavioral Neuroscience Society, 
Volunteer Head Coordinator: June 2014. Initiated the first annual philanthropy event 
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for the International Behavioral Neuroscience Society where we raised over $1000 to 
donate to the local community (Clark County School District’s Safe Routes to School 
Program). In addition, I implemented and organized an educational outreach event in a 
local school (Wright Elementary School) where we educated the students on brain facts 
and safety.   
Las Vegas Brain Bee Organizer: February 2014. Appointed as the Logistics 
Coordinator for the Las Vegas Brain Bee. Participants were local high school students 
demonstrating their knowledge in neuroscience. The winner from this competition was 
sent to the National Brain Bee. 
Nevada Brain Bee Association, Co-Founder and Board Member: Fall 2013 – present. 
Under the umbrella of the International Brain Bee Association, the Nevada Brain Bee 
Association held the Inaugural Las Vegas Brain Bee in February 2014. This annual event 
is for high school students to demonstrate their knowledge of the brain and compete for a 
spot at the National Brain Bee to represent the state of Nevada. The winner at our 
Inaugural Las Vegas Brain Bee took third place overall in the National Brain Bee 
competition in March 2014, putting Las Vegas on the map for neuroscience education.   
Brain Awareness Campaign, Head Coordinator at UNLV: Fall 2012 – present. The 
Brain Awareness educates the public and promotes brain science at local schools and 
community centers. Funding for these events provided by the Sierra Nevada Chapter of 
Society for Neuroscience ($200 in 2013 and $650 in 2014).   
APS Mentorship Program: Fall 2010 – present. The APS Mentorship Program helps 
undergraduate students with career plans and future goals by pairing them with a 
graduate student to form a peer-mentor relationship.   
 
 
 
